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Abstract
Granular Cell Tumours (GCTs) are rare subepithelial lesions that are believed to develop from
Schwann cells and are characterized by large polygonal cells with abundant lysosomes. Pilot
studies from our laboratory showing unexpected HLA-DR immunoreactivity in GCTs lead us to
hypothesize that GCTs have an antigen presenting cell (APC) phenotype.
To test our hypothesis, we assessed immunoreactivity of GCT lesions to APC phenotype markers,
including CD68, HLA-DR, CD163, CD40 and CD11c. In addition, we assessed markers of neural
crest cell (NCC) origin S100, SOX10, NSE and GAP43. Samples subjected to these studies included
23 cases of GCTs and 10 cases of Schwannomas, used as comparators. To confirm the key
findings, we detected transcript levels of select genes using quantitative polymerase chain
reaction..
We identified a new NCC marker for GCTs, GAP43. We also provide evidence of an APC phenotype
of GCTs, as determined from CD68 and HLA-DR immunoreactivity. Due to the limited nucleic acid
yield from paraffin-embedded GCT sections, we were unable to draw conclusions from transcript
assessment.
Keywords: Granular Cell Tumour, Schwannoma, S100, SOX10, Neuron Specific Enolase, GAP43,
HLA-DR, CD68, CD163, CD40, CD11c, SOX2, SOX9, Nestin, GFAP, beta-Tubulin-3, and beta-actin,
NF
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Summary for Lay Audience
Granular Cell tumours (GCT) are rare benign nodular lesions that develop in the connective tissue
below the skin. Our current understanding is that these tumours develop from tissue-supporting
cell types called Schwann cells. Schwann cells support the peripheral nervous system. Based on
pilot work completed in our lab, GCTs appear express a protein that is commonly found on
immune cells. Based on these studies, we hypothesized that the cells making up GCTs have a
cellular appearance or behaviour similar to cells in the body whose job is to identify foreign
material, such as bacteria or viruses. To test our hypothesis, we obtained tumour tissues and
examined whether these tissues express other proteins that would strengthen an immune celllike property. We were able to identify one additional protein that is primarily found in immune
cells: CD68. A panel of other proteins tested were not found. While there are similarities in the
appearance of the granular cells and immune cells, the evidence is not conclusive. One key
finding, however, is that GCTs express a new protein called GAP43 which is important in the
growth of new nerves and is found in Schwann cells following nerve injury. The presence of
GAP43 protein in the granular cells of GCTs provides strong evidence that GCTs develop from
Schwann cells. Future studies from our lab will focus on whether granular cells are more like
mature or immature Schwann cells.
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Chapter 1
1.0 Introduction
Granular Cell Tumours (GCTs) are thought to be derived from cells originating from the neural
crest, specifically Schwann cells. While there is a body of evidence to support a neural crest origin
for GCTs, little has been done to explore the granular appearance of GCTs. A serendipitous
discovery in our lab of a case of GCT that stained for Human Leukocyte Antigen – DR isotype (HLADR) during an investigation of Langerhans cell lesions of the tongue, led us to theorize that GCTs
granular appearance is an Antigen Presenting Cell (APC) phenotype. In the introduction I will
provide a comprehensive review of our current understanding of GCT tumorigenesis, neural crest
cell embryology and differentiation to Schwann cells, and provide a review of our current
understanding of Schwann cell derived benign peripheral nerve sheath tumours. I will also
introduce and discuss the experimental setup and the rationale behind specific markers
investigated.

1.1.0 Granular cell tumours
Granular cell tumours ( GCT) are relatively rare soft tissue lesions whose etiology has been a focus
of interest for many years. The current understanding is that the granular cells of GCTs originate
from Schwann cells (SCs), based primarily on the immunohistochemistry profile of GCT and
Schwannomas. In this chapter I will review the epidemiology and current understanding of GCT
origin and tumourigenesis with a focus on intraoral lesions.
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1.1.1 Epidemiology of Granular cell tumours
Granular cell tumours are relatively uncommon sub-epithelial entities usually presenting as a
solitary benign lesion; however multifocal and malignant cases are reported1. It is estimated that
50% of all GCTs occur in the head and neck region, with the tongue being the most common site
representing 23 to 28% of all lesions and 65 to 85% of intraoral lesions1. Other common sites
include the connective tissue of cutaneous epithelium, breast, esophagus, tracheobronchial tree,
gastrointestinal tract, biliary tree and genitourinary tract1. Although exceptionally rare, there
have been case reports of plexiform variants of GCT within peripheral nerves 2. Literature on
GCT epidemiology is poor and mostly from case series. The largest case series was published in
1980 by Lack who reviewed the epidemiological data for 110 individuals with GCTs. He identified
the age range to be 16 to 58 years with a mean age of 32. He showed a gender predilection of
males to females of 2:1, and a race predilection of white to black individuals of 3:1. Six of the
cases had multiple GCTs3. A 1969 report by Vance and Hudson reviewed data from 48 cases of
GCT. They found the youngest patient was 11 months, with the oldest being 68 and a mean of
37 years old. He identified a female predilection of 2:1, and that 75% of cases occurred in black
individuals4. A third large case series was published by Khansur who identified 37 lesions over a
20-year period at their institution. In this case series, age ranged from 6 months to 73 years with
a median age of 31. Two patients presented with multiple lesions, and 3 cases demonstrated a
familial occurrence. There was no gender predilection; and the race predilection was 2:1 for
black to white individuals5. Based on scarce evidence, the estimated incidence of multiple GCT
ranges widely. However, literature on GCTs of the aerodigestive tract suggests multiple lesions
occur in 2-10% of cases6. There are also reports suggesting an incidence of 7-29% for multiple
cutaneous GCTs, seeming to occur in younger-aged patients 7. Despite the variability of the
reported epidemiology data, the World Health Organization (WHO) cites the most common age
group to be the fourth and sixth decade. It also cites a predilection for females over males of
2:18.
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The size of GCTs at the time of diagnosis varies widely depending on the site of presentation, and
they are generally thought to be slow-growing indolent lesions. In the oral cavity, the mean size
at presentation and treatment is 2 cm, with the majority of lesions being treated before 3 cm in
size1. Tumours larger than 5 cm in diameter are suspicious for malignant transformation9.
Clinically, they present as unassuming subepithelial firm round nodules and are generally
asymptomatic, however large legions can be obstructive such as in the esophagus, or biliary
tree10. Following surgical excision, GCTs tend not to reoccur. Recurrence rates have been cited
as 20% for incompletely excised lesions and at 2-8% of lesions with surgically clear margins11. In
cases of reoccurrence with surgically clear margins, it is theorized that tumour extensions likely
remained rather than a true recurence12. Given the low recurrence rate and benign nature of
GCTs narrow margin excision is the recommended treatment, and while not required,
consideration may be given for intraoperative frozen section. Additionally they are nondescript
on imaging and, especially for larger lesions, may be interpreted as an invasive lesion on
computerized tomography (CT) or magnetic resonance imaging (MRI)13.

1.1.2 Histology of Granular Cell Tumours
Gross examination of a GCT is consistent with a tan/pale colored, rubbery, and poorly
circumscribed nodule without a capsule. Histologically, these lesions are composed of larger than
average polygonal or lozenge shaped cells of varying size with abundant cytoplasmic eosinophilic
granules and small eccentric nuclei. The granules are periodic acid Schiff (PAS)-positive and
diastase-resistant3. The granules additionally stain positively with Luxol fast blue stain1. There is
no recognized architectural arrangement of GCTs, but tumour cells are arranged in clusters or
sheets with thin/scant bands of connective tissue interspersed. The periphery of the tumour is
poorly delineated and at times, appear to merge both with the overlying epithelium and with the
underlying skeletal muscle giving an infiltrative appearance. Additionally, there is often detached
clusters of cells that can be found a distance from the bulk of the tumour, likely representing
tumour extensions rather than budding lesions1. There are also varying reports of the prevalence
of small nerve at the periphery of lesions suggesting there is an association between GCTs and
3

perineural cells, and may implicate a lesion that occurs following axonal injury1. Nearly 50% of
cases show evidence of pseudoepitheliomatous hyperplasia, an inflammatory reaction of the
epithelium, with increased epithelial thickness and elongated rete ridges. It may be mistaken for
squamous cell carcinoma (SCC) by a pathologist unfamiliar with the lesion, confounded by the
rarity of GCTs and the relatively high incidence of SCC 14,15. Cytology after fine needle biopsy is
challenging and can often be confused with other tumour cells with granularity such apocrine
metaplasia/carcinoma in breast cancer which may result in unnecessary surgery16.

1.1.3 Tumourigenesis of Granular Cell Tumours
GCTs were first described by Weber and Virchow in 1854 using light microscopy as a lesion
characterized by clusters of large cells of an unknown origin with eosinophilic granular cytoplasm
13

. Their work was expanded on by a Russian Pathologist Abrikossoff who identified several

lesions with a similar appearance arising within the tongue. He theorized that the lesions arose
from myoblasts of the underlying skeletal muscle, and named the tumour myoblastenmyome or
myoblastoma1.

As microscopy techniques became more sophisticated, including the

development and use of electron microscopy (EM), myogenous origin has since been disproven.
The first evidence to refute a myogenous origin came from EM studies showing GCTs to be
invariably separated from skeletal muscle by bands of collagen without a transitional zone and
no evidence of myofibrils17. EM also identified that the granules of GCTs were most consistent
with lysosomes/autophagic vacuoles, and secondary intermediate lysosomes including some
vacuoles that contained virus like particles suggesting a possible histiocytic origin17,18. Other EM
studies identified vacuoles containing lipoproteins and syringolipids, which were presumed to be
degraded myelin, and microtubules. Given the proximity of such a cell to axons near the tumours
periphery indicated a possible common precursor to Schwannomas17,19. Finally a third theory
developed using EM was that GCTs arose from undifferentiated mesenchymal precursors of
fibroblasts that had phagocytized cellular debris17.
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While EM raised many questions, it was not able to provide many answers. Much of what we
now know about GCTs etiology has come from immunohistochemical staining (IHC). One of the
first groups of IHC antibodies to be studied marked skeletal muscle: myoglobin, myosin, actin and
desmin, all of which consistently stain negative giving further evidence to refute a myogenic
origin20,21. Investigating the theory that GCTs were of neural sheath origin, Mukai completed IHC
staining for S100 and myelin protein P0 and P2. S100 belongs to a small molecular-weight protein
family, initially thought to be only found in in neural tissue. He found positive staining in 18/18
GCTs for S100, P0 and P2, with P0 and P2 staining the PAS-positive granules. Give that histocytes
generally stain negative for S100, he provided evidence that granular cell tumours were likely
derived from SCs and theorized that the GCT cells produced myelin rather than phagocytizing
myelin debris21. Stewart also assessed immunoreactivity of S100, in addition to enzymes
common to histiocyte vacuoles: muramidase and alpha-1 antitrypsin. S100 was diffusely positive,
while muramidase and alpha-1 antitrypsin were negative suggesting that GCTs arose from neve
sheath cells20. More recently, GCTs have been found to stain positive with a number of other
antibodies associated with nerve sheath cells including SOX10, p75NTR and Neuron Specific
enolase (NSE), a nonspecific glycolytic enzyme thought to be associated with neural
inflammation12. Additionally GCTs are reported to stain for vimentin, and weakly or negatively
for glial fibrillary acid protein (GFAP) provide evidence that the microtubules seen on EM are
likely structural proteins common to glial cells22. Other IHC antibodies thought to indicate a
neural origin that have been found to stain positive include: Calretinin, a calcium binding protein,
and PGP9.5 protein, a hydrolase enzyme thought to be expressed primarily by neural tissue22,
although both have been since been proven to be non specific23,24. There is also evidence of IHC
staining for neural cell adhesion molecule neural cell adhesion molecule (NCAM), a cell-cell
binding protein integral to the structure of nerves.
In contrast to the cell markers suggesting a neural origin, GCTs show immunoreactivity to
endomesenchymal antigens.

Gurzu found that GCTS stained positive for antibodies to

macrosialin (CD68), a transmembrane glycoprotein associated with lysosome membranes. Five
of the 15 cases in their series demonstrated positive staining for the proto-oncogene tyrosineprotein kinase receptors c-kit and RET. Five cases showed loss of staining for NCAM. Given that
5

the cells were S-100 positive, NCAM negative but positive for c-kit and RET, he theorized that
GCTs were “glial like” but of endomesenchymal origin12. GCTs have also been shown to stain for
CD63, a tetraspanin glycoprotein localized to lysosomes and cell membranes of cells with
autophagosomal action, in addition to being a tumour marker of a variety of different tumours
of both endodermal and ectodermal origin25. Another antibody identified to stain positive was
anti-3, which is reactive for the microtubule-associated protein 1 light chain 3, a specific marker
for autophagay26. Serendipitously, in an unpublished study our lab identified positive staining of
a GCT section for the antigen presenting cell marker HLA-DR while investigating Langerhans cells
of the tongue. This surprising finding has only been reported in one other investigation27. While
the likely cell of origin are SCs, HLA-DR and CD68 immunoreactivity suggest an antigen presenting
cell (APC) phenotype for GCTs. Additionally, considering the available evidence provided by IHC
it is not clear if GCTs are true neoplasms or reactive in nature.
While thought to originate from neuroectodermal cells, there is limited understanding of the
cellular events that result in GCT formation. Resulting from reports of patients with multiple
GCTs, researchers have tried to identify a possible genetic cause for GCTs. There are three
reported cases of multiple GCTs in a patient with a diagnosis of LEOPARD syndrome, 28,29, and 7
case reports of patients diagnosed with Noonan syndrome presenting with multiple GCTs30.
LEOPARD syndrome and Noonan syndrome are related conditions that arise from an activating
mutation of the protein tyrosine phosphatase non-receptor type-11 (PTPN11) gene on
chromosome 12 (12q24.13). LEOPARD syndrome characteristics include: clinical cluster of
lentigos, electrocardiographic conduction defects, pulmonary stenosis, abnormal genitalia,
intellectual impairment, short stature and deafness31; while Noonan syndrome is characterized
by a characteristic facial dysmorphism with cardiac defects, short stature, broad or webbed neck,
and a variable learning disability32. PTPN11 is an oncogene that codes for an auto-inhibitory
protein Src homology region 2-containing protein tyrosine phosphatase-2 (SHP-2) which is part
of the Ras/MAPK signalling pathway. Normally, binding of a phosphorylated tyrosine residue
disinhibits SHP-2, resulting in signalling for cell growth, proliferation, differentiation and
migration. Thus, the activating mutation of PTPN11 results in sustained activity of the Ras/MAPK
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signalling pathway and sustained growth signals33. While there is a correlation between Noonan
and LEOPARD syndrome and multiple GCTs, PTPN11 mutations do not appear to be causative in
the tumourigenesis as additional studies have not found a PTPN11 mutation in solitary granular
cell tumours 34. There is also at least one report of a mother and child with diagnosis’ of NF1,
both presenting multiple cutaneous GCT35, however there does not appear to be a strong
correlation between GCTs and NF1 mutations.

More recently, after the onset of our

investigation, a novel mutation in ATP6AP1 and ATP6AP2 genes associated with endosome
acidification have been identified by Pareja et al. using whole-exon sequencing36. In the initial
cohort of 17 GCTs, they were unable to identify any known oncogenic genes or pathogenic fusion
genes. They did however discover novel inactivating mutations of ATP6AP1 and ATP6AP2 in 12
of the 17 tumours. They then subjected 65 additional GCTs to targeted gene sequencing and
identified somatic mutations of ATP6AP1 in 36/65 cases and ATP6AP2 in 6/65 cases. In total, 72%
of the GCTs demonstrated either ATP6AP1 or ATP6AP2 mutations. They also investigated gene
sequencing data of 6285 cases of malignancy from among 14 cancers in the Cancer Genome
Atlas, and 103 cases of histologically similar lesions including Schwannomas, paragangliomas,
adrenocortical carcinomas, oncocytomas, hibernomas, and chromophobe renal carcinomas.
From these lesions, they identified ATP6AP1/ ATP6AP2 mutations in 0.03 and 0.05% of the
malignancies, respectively and no mutations of ATP6AP1/ ATP6AP2 in the other soft tissue
lesions36. ATP6AP1 and ATP6AP2 genes are found on the X chromosome, Xq28 and Xp11.4
respectively, and code for accessory proteins of vacuolar H+-ATPase (V-ATPase). V-ATPase,
composed of the subunits V0 and V1, is found in the membranes of endosomes and functions to
acidify secretory vesicles and lysosomes. The accessory proteins coded by ATP6AP1 and ATP6AP2
are required for V-ATPase insertion during endosomes formation at the Golgi apparatus and have
an additional role in vesicle trafficking37. Pareja was successful in achieving a granular cell
transformation of an immortal Schwann cell line, human embryonic kidney (HEK)-293 cell line
and non-tumourigenic mammary epithelial MCF-10 cell line through in vitro depletion of
ATP6AP1 and ATP6AP2. These granular cells also demonstrated reduced acidification of vesicles
as a result of reduced V-ATPase function. They theorized that the accumulation of endosomes
was a function of both altered vesicle trafficking and a loss of endosomal function as a
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consequence of altered pH36. Following the work of Pareja, there has been additional research
into other potential mutations that could affect the function of V-ATPase. Sekimizu et al.
performed gene sequencing on 51 GCTs and identified mutations of genes encoding for V-ATP
subunits and accessory genes in 33/51 cases (65%)38. ATP6AP1 mutations were identified in 23
cases and ATP6AP2 mutation identified in 2 cases. Additionally there were found to be mutations
of 1 other V-ATPase accessory protein, in addition to mutations of 6 different V-ATPase subunits
of both V1 and V038. Collectively, the evidence suggests that the genotype-phenotype correlation
is related to V-ATPase dysfunction. The mechanism of tumourigenesis following mutations that
disrupt V-ATPase activity is still unclear, however it has been theorized that changes in
endosomal function results in altered cell signalling in an independent fashion giving GCTs
oncogenic properties36. These findings provide evidence of a mutation that likely contributes to
an APC phenotype of granular cell tumour.

1.1.4 Malignant Granular Cell Tumours
Malignant GCTs (m-GCT) are classified as high-grade sarcomas due to their aggressive behavior,
lack of response to treatment and poor clinical outcomes. While thought to develop from benign
GCTs, it is also possible they are a different tumour with a similar phenotype39. Reports suggest
that malignant variants represent 2% of all GCTs and 0.2% of soft tissue sarcomas40. Metastasis
has been reported to lymph nodes, lung, bone, nerve, and peritoneum41. The accepted
classification system for determining malignant transformation is the Fanburg criteria. Fanburg
et al, reviewed 73 cases of atypical GCTs under light microscopy in an attempt to identify features
that could be used to classify GCTs as malignant or lesions with high risk of malignancy39. They
proposed 6 histological criteria: necrosis, spindling, nuclei with large nucleoli, increased mitotic
activity (2 or more atypical mitoses/10 fields at 200x magnification), high nucleus to cytoplasm
ratio, and pleomorphism. They concluded that lesions meeting 3 or more criteria should be
diagnosed as malignant and, 2 or less as benign with atypical features. Of the 73 lesions in their
report, 46 were classified as malignant, with 28/46 of the malignant cases having metastasized
and 0/27 of the atypical cases having metastasized. IHC of the malignant cases showed no
8

significant difference between malignant and benign cases for S100, vimentin, and NSE,
commonly used markers for GCTs. They also stained tumours with Ki67, a marker of cell
proliferation, and found a statistically significant worse prognosis if Ki67 was >10%. Other
authors suggest that metastasis should be the sole criteria for diagnosing a malignant GCT (MGCT), while recognizing the Fanburg criteria as a risk stratification method42. In the largest review
of M-GCT involving 113 patients, the median age was 54 and 77% of patients were female. The
average reported size of malignant lesions was larger than reported for benign lesions at 4 cm,
although 53 of the cases did not report tumour size. A true value for rate of metastasis could not
be calculated due to poor reporting. There was a significant difference in patient survival for
tumours larger than 5 cm, with 5 year survival of 51.3% for lesions >5 cm and 90% for lesions < 5
cm. Survival at 5 years was 0% for patients with reported distant metastasis43. In another study,
the 3 year survival was 39% for metastatic disease39. M-GCT of the oral cavity is extremely rare,
although there is one case report from India that diagnosed an 11 cm M-GCT in the base of
tongue causing ankyloglossia without metastasis44. The rarity of oral M-GCT is cited to be related
to tumour size at the time of diagnosis 44. Thus far, surgical excision is the only curative choice
as radiation and chemotherapy have not demonstrated increased survival with worse patient
outcomes43. There has been one case of M-GCT that underwent whole genome sequencing. This
study identified a total of 12 genetic mutations in the single case of M-GCT, most of which had
an unknown significance at the time of the report, including a mutation of ATP6AP1. There was
one known loss of function mutation of the tumour suppressor gene BRD7, a subunit of PBAFspecific SWI/SNF chromatin remodeling complex, known to be a regulator of BRCA145. While the
study only looked at 1 case of M-GCT it is of interest that they identified a mutation of ATP6AP1,
in addition to BRD7 a gene that has been shown to be a tumour suppressor gene in breast
cancer46. Further investigations can hopefully elicit a possible targeted therapy for GCT, which
may be patient specific depending on the genotype of the tumour cells.
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1.2 Embryology of neural crest cells
Despite vast knowledge of the development, migration, and differentiation of neural crest cells
(NCCs) from the neural crest to their respective cell populations, it is still somewhat poorly
understood. I will provide a brief summary of the process of migration and differentiation with a
focus on peripheral perineural glial cells.

1.2.1 Formation of the neural crest
At approximately day 16 of human embryo development, the single layered blastula is
reorganized into the trilaminar gastrula, via a process called gastrulation, forming the ectoderm,
mesoderm and endoderm. This process also defines the rostral and caudal ends of the developing
embryo, and the midline axis at the notochord. During the third week of development,
neurulation occurs forming the neural plate from ectodermal cells located below the notochord,
which then invaginates to form the neural tube. During the folding process, the dorsal marginal
ectodermal cells are pulled inward to form the neural crest (NC) sandwiched between the nonneural ectoderm and the neural tube. The neural tube will later develop to become the brain
and spinal cord while the neural crest remains as a pluripotent cell population that will continue
to migrate and form a wide variety of cell populations47.

1.2.2 Migration of neural crest cells
Neural crest cells (NCC) undergo the most varied and complex migration of all cell types in the
developing embryo and are often referred to as a fourth germ later due to its significance. Much
of the early work in the study of NCC migration was done by LeDourain in the 1960s who grafted
quail NCCs into chicken embryos, generating a chimera. Using light microscopy and later antibody
labelling, LeDourain identified several different clusters of NCC at different levels of the embryo
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axis and termed the clusters cranial, vagal, trunk and lumbrosacral populations48. The cranial
level cells contribute to cranial sensory ganglia, the cartilaginous precursors of the facial skeleton,
dental papilla, the dermis, smooth muscle, adipose tissues of the head and neck, and the salivary
glands. Vagal and sacral neural crest cells populate the gut, forming the enteric nervous system
and the outflow tract of the heart in addition to the vagus nerve, while the trunk neural crest
cells form sensory and sympathetic ganglia and the adrenal medulla. Cells from all levels
contribute to the formation of the sympathetic and parasympathetic nervous system, pigmented
cells of the epidermis and peripheral glial cells49,50.

1.2.3 Neural crest cell differentiation
There is some debate regarding the terminal differentiation of NCCs, with evidence to support
both fate restriction and retained multipotency. Fate restriction refers to a process where the
terminal cell lines are determined prior to migration, and retained multipotency suggests that
the terminal cell line is determined following migration while the stem cell characteristics are
retained late into cellular maturation. Regardless of which theory one attest to, there is evidence
to suggest that the environment to which stem cells migrate to plays a key role in determining
their terminal cell type fate. During NCC differentiation, there are both permissive and repulsive
extracellular matrix cues that result in differential gene activation51, initiating the progression of
NCCs towards their terminal cell type fate52. In the case of Schwann cells (SC), the process of
NCCs differentiating to Schwann cell precursors (SCP) is a process referred to as peripheral
gliogenesis53. One of the key transcription factors identified in peripheral gliogenesis and
differentiation of other NCC cell lines is SOX10, a member of the RY-related Homeobox box (SOX)
family of transcription factors. SOX10 interacts with a number of other proteins in a contextspecific fashion to promote differential gene transcription playing a key role in determining cell
line fates52,53,54. A functional role of SOX10 in gliogenesis is supported by evidence that knock
out mice lack peripheral glial cells resulting in a neurodegenerative condition55. In humans, there
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are a number of conditions that result from heterozygous SOX10 mutations, such as
Hirschprung’s Disease and Waardenburg Syndrome in which there are myelination defects of
peripheral nerves56. The signalling cascades involved in NCC maturation are complex, but key
ligands have been identified as playing important roles. One of these signaling molecules in
peripheral gliogenesis is neuregulin-1 (NRG-1), a growth factor which supresses neuronal
development and promotes glial specification57. NRG-1 is a protein ligand of the ErbB receptors
tyrosine kinases (ErbB1-4) transmembrane epidermal growth factor family receptors. ErbB3/4
activity has been shown to result in upregulation of SOX10 expression52 although the intracellular
mechanism for promoting SOX10 is unclear55.

An example of a transcription factor that is

differentially expressed during peripheral gliogenesis is SOX2, another member of the SOX family.
SOX2 has been found to be upregulated in SCP but downregulated in both NCCs and absent in
mature SCs. SOX2 acts to inhibit the induction of Krox20, a zinc finger transcription factor
required for myelination of axons and promotes proliferation of SCP58. In contrast to SOX2,
SOX10 is persistently expressed in cells with neural, glial and melanocyte fates while other NCC
derived cell lines downregulate SOX10 in their mature cell lines53

1.3 Schwann cell
Schwann cells are the principal glial cells of the peripheral nervous system. I will outline their
function and the steps in progressing from SCPs to immature Schwann cells and maturation to
myelinating SCs and non-myelinating SCs.

1.3.1 Schwann cell precursors to myelinating Schwann cells
Schwann cells develop from SCPs located in the boundary cap region, which are clusters of NCCs
on the surface of the neural tube, at the exit points of the developing peripheral nerve roots59.
The first step in differentiation from SCPs to immature SCs is a process referred to as radial
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sorting. During radial sorting, SCPs polarize, undergo functional and structural changes and align
themselves parallel to developing axons52. There is evidence to suggest that this process is
regulated by signaling cues from the developing axon rather than being intrinsic to the SCP or
that axonal growth is guided by the SCPs.

Neural derived ligands include brain-derived

neurotrophic factor (BDNF) and nerve growth factor (NGF) whose substrate is protein 75 low
affinity nerve growth factor receptor /neurotrophin receptor (p75NTR) and NRG-160. During radial
sorting, SCP will either associate with a single large caliber developing axon in a 1:1 ratio resulting
in a pro-myelinating SC fate or associate with a number of small caliber axons resulting in nonmyelinating remark SC53. The pro-myelinating SC then develop finger like lamellipodia
cytoplasmic projections that start to ensheath the developing axon in 40 or more layers, while at
the same time synthesizing the cytoskeleton, and laying down an extracellular matrix forming a
basal lamina52. Components of the cytoskeleton include glial fibrillary acidic protein (GFAP) and
vimentin. As the cells mature, vimentin remains as an integral structural protein while GFAP is
downregulated61. Late pro-myelinating SC at this point in maturation are organized into
adaxonal, paranodal, internodal and abaxonal cellular compartments. The adaxonal surface is in
tight contact with the axon, and is rich in adhesion molecules interacting with ligands of the axon.
At each end of the cell is the paranodal region that binds to the associated axon through tight
junctions resulting in the nodes of ranvier62. The outer abaxonal compartment contains the
nucleus, is rich in cellular organelles and also binds to the basal lamina via integrin proteins62.
The internodal compartment eventually becomes the tightly wrapped myelin rich compartment
during cell maturation from pro-myelinating SC to myelinating SC 63. As the cell matures there is
a shift to down regulate transcription factors and cell signals that inhibit myelin formation and
upregulate pro-myelination transcription factors and signals. One of the key cellular events is
the downregulation of SOX2, which removes the zinc-finger transcription factor (Krox20)
inhibition. Krox20 is a pro-myelinating transcription factor that functions synergistically with
SOX10 and the pro-myelinating POU domain transcription factors Oct6 (Pou3f1) and BRn2
(Pou3f2)64,59. A target of SOX10 are the histone deacetylase HDAC1 and HDAC2, that promote
pro-myelinating genes such as myelin protein zero (P0). HDAC1/2 knockout mice show arrest of
SCP in the pro-myelinating state65. On a larger scale, SCP migration and organization also play an
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important role in the formation of nerve fascicles. Another role of SCPs is to help guide sprouting
axons to make contact with their targets via clusters of SCP that advance at the leading edge of
axonal growth cones during development of the peripheral nervous system53.

1.3.2 Function of Schwann cells
As the principle glial cells of the peripheral nervous system, Schwann cells have many different
roles, with similar but different roles for: myelinating SCs, non-myelinating remark cells, and
other specialized non-myelinating SC. Each myelinating SC spans approximately 100 um along a
single axon and functions to increase conduction velocity along axons by ten times via a process
known as saltatory conduction66. During salutatory conduction action potentials propagate at
unmyelinated gaps between adjacent SC, nodes of Ranvier, while the dense myelin sheath of the
internodal cellular compartment acts to insulate the action potential restricting sodium influx to
the high voltage channels of the nodes of ranvier67. The paranodal region appears to have a role
in inducing the expression of these high voltage electrolyte channels by the neuron and tightly
binds to the axon via contact-associated paranodin cell adhesion molecule (caspr) among other
proteins restricting ion influx to the nodal regions68. Myelin of the internodal compartment has
a high lipid content, and is enriched with galactosphingolipids, saturated long-chain fatty acids,
and cholesterol69. The primary structural protein of myelin is myelin protein zero (P0) belonging
to a family of membrane adhesion molecules. each P0 spans the cellular membrane to ensure
tight coiling of the internodal compartment via interaction of transmembrane hydrophobic
domains while binding to other P0 domains in the intracellular compartment70. In addition to P0
there are a number of other myelin proteins found in higher concentration in the peripheral
nervous system relative to the central nervous system including myelin protein 2 (P2), peripheral
myelin protein 22 (PMP22) and myelin basic protein with similar structural roles to P071. Other
functions of myelinating SCs include regulation of axonal diameter and neurofilament spacing.
SCs also provide metabolic support for their associated neuron as several studies report that
mitochondrial dysfunction in SC results in degeneration of the axon, but not the SC72.
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Populations of Non-myelinating SC include remark cells, presynaptic SC, and satellite glia cells of
peripheral ganglia. Each Remark cells associates with several non-myelinated axons via cellular
extensions that cluster non myelinated axons into bundles referred to as remark bundles73.
Perisynaptic SCs encase neuromuscular junctions; and satellite glia cover the surfaces of nerve
cell bodies in sensory, sympathetic and parasympathetic ganglia. Both groups appear to have
roles in maintain synapses and regulating the perisynaptic environment through uptake of
neurotransmitters74.

1.3.3 Role of Schwann cells in nerve injury
In the peripheral nervous system, axons are bundled together in an organized multilayered
fashion to form nerves. Each axon and their associated SCs are encased in a fibrous endoneurium
known as funiculi. Funiculi are then bundled together and are encased in a second fibrous layer,
the perineurium, resulting in the formation of fascicles. Fascicles are then bundled and encased
in the outer fibrous membrane, the epineurium, an extension of the fusion of arachnoid and pia
matter as a nerve exits the spinal foramen75,73. Nerve injuries are generally classified according
to level of discontinuity of the respective nerve. Axonotmesis, axonal discontinuity with an intact
endoneurium, has an excellent prognosis for re-establishing contact at the distal synapse.
Injuries that result in discontinuity of axons and their fibrous sheath, neurotmesis, have a
significantly worse prognosis for regaining function as a result of poor selectivity of axon-target
reconnection76. Following loss of axonal continuity, there is death of the distal segment in a
process known as Wallerian degeneration. As myelinating SCs lose contact with their associated
axon, there is a change in the cellular environment that no longer favors the myelinating
phenotype of SCs, and myelinating SCs dedifferentiate to repair Schwann cells (RSC). Three key
ligands that are implicated in this process include calcium, NRG-1, and Fibroblast Growth Factor2 (FGF-2), all of which are found in increased concentration following Wallerian degeneration77.
During dedifferentiation, the transcription factor c-jun is activated resulting in upregulating of
both SOX2 and an additional transcription factor Pax-3. Upregulation of SOX2 inhibits the pro-
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myelinating transcription factors Oct-6 and Krox-20 inhibiting myelination. This results in both
myelinating SC and non-myelinating SC dedifferentiating to RSC, a phenotype of SCs that is very
similar to SCPs73,77,78,79. RSC undergo myelin autophagy, phagocytize degraded myelin sheath,
and release cytokines that signal for macrophage ingress to assist in debriding neural and myelin
debris. RSC then reorganize into repair tracts along the basal lamina called bunger bands
effectively maintaining an environment for new axonal growth75,77. Simultaneously, the neuron
undergoes a process referred to as the cell body response, switching from a transmission state
to a growth state resulting in growth cone formation at the proximal stump76. Growth cones are
characterized by several lamellipodia that respond to signals including both neurotrophic and
neurotropic factors released from the cells of the bunger bands, such as glial derived
neurotrophic factor (GDNF), NRG-1 and Growth associated protein 43 (GAP43) to promote axon
elongation76,78. As the growth cone advances, signalling cues from the maturing axon result in
redifferentiation of the RSC back to myelinating SC in a process that is similar to development73,80.

1.4 Schwann cell neoplasms
Schwann cell neoplasms are classified as peripheral nerve sheath tumours (PNST) and include
Schwannomas, neurofibromas (NF), and malignant peripheral nerve sheath tumours (MPNST).
The cellular processes that result in PNST are poorly understood but thought to occur following
nerve injury. More commonly, PNSTs will arise as isolated lesions, but much of what we know
about the process that results in the formation of PNST comes from research of genetic
conditions such as neurofibromatosis type 1 (NF1), neurofibromatosis type 2 (NF2), Carney
complex type 1 and Schwannomatosis, conditions characterized by the formation of multiple
PNST in a variety of anatomical locations81. I will discuss our understanding of the underlying
cellular processes that result in PNST with focus on intraoral Schwannomas.
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1.4.1 Neurofibromas
Neurofibromas have a propensity for forming in the dermal layer of the skin, but plexiform NFs
deeply situated within nerves, most commonly in large nerves of the extremities, do occur82.
Clinically, they are described as unencapsulated ovoid, grey or tan colored firm masses and are
generally smaller than 2 cm in diameter. A distinguishing feature is the button-hole sign where
the lesions retract into the underlying tissues on palpation and then reappear on release. In
dermal NF, there is also a characteristic violaceous skin change83. Histologically, they are
composed of varying numbers of SCs and fibroblasts with the SCs recognized as the neoplastic
cell type making up 40-80% of the lesion84. There is great architectural variety and they are
described as a of “bag of worms”, due to the mix of spindly SCs, fibroblasts and axons; however,
the spindle SCs and fibroblasts are found in clusters. The stroma is dense in poorly organized
collagen bundles. Transected or damaged axons are often found adjacent to the lesion suggesting
that they form following nerve injury. Dermal NF form in the subcutaneous tissue and have a
Grenz zone, normal dermis between the lesion and the overlying epidermis. Approximately 90%
of neurofibromas will appear sporadically as an isolated lesion, while the remainder occur in
patients with NF182. They are generally thought to be benign, however malignant transformation
can occur resulting in MPNST.

The age of onset is variable; however they most commonly

develop in young adults in the 3rd to 5th decade of life. Patients with NF1 develop multiple NFs,
both dermal and plexiform types. NF are often asymptomatic with chief complaints of pruritis,
pain, or paresthesia, but the most common complaint is cosmetic appearance85.
Much of what we know about the cellular process that result in the formation of NF comes from
research in the condition NF1. NF1 effects 1 in 2500 to 3500 patients. The condition is either
inherited in an autosomal dominant fashion with complete penetrance but variable expression
or occurs as a de novo mutation in as many as 50% of cases84. While the characteristic lesion of
NF1 is multiple dermal NF, they do also develop plexiform NF, have reduced intelligence, and
other tumours including boney dysplasia, optic gliomas, Lisch nodules, glioblastomas,
pheochromocytomas, and gastrointestinal stromal tumours among others84. Research in the
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1990s identified a mutation on the long arm of chromosome 17 (17q11.2) that coded for a large
gene called neurofibromin (NF1 gene)86. Complete deletion is rare, with nonsense, frameshift
and missense mutations more commonly identified. There is also great variability in genotypephenotype correlation87. DNA analysis of isolated NFs in patients without NF1 has also identified
mutations in the NF1 gene; suggesting that mutation of NF1 is required for NF formation88. The
NF1 gene has multiple functional domains, however mutations do not always result in NF
formation suggesting that there are key domains that are still being explored87. The NF1 gene
appears to be a tumour suppressor gene, as research suggests that a “second hit” to the wild
type allele results in tumourgenesis. Loss of heterozygosity is also seen88,87. The Neurofibromin
gene encodes for a protein with a similar structure to GTPase-accelerating protein (GAP).
Neurofibromin protein binds to Ras GTPase, which is a hub protein associated with a wide variety
of transmembrane receptors. Ras GTPase functions as a binary control for signal transduction by
cycling between the inactive GDP-bound form and active GTP-bound form facilitated by GAP. By
inhibiting the GAP-Ras GTPase interaction, neurofibromin effectively inhibits the conversion of
GTP to GDP resulting in downregulation of Ras activity84,89. Mutation of neurofibromin results
in upregulation of Ras signaling which results in cell proliferation and increased cell survival
among other cellular functions89,90. NF1 Knockout mice variably develop NF, and it is yet unclear
which cell stage of SC are responsible for NF formation84. Recently, there is evidence to suggest
that in addition to NF1 mutation, other growth factor signals are required. One candidate is
NRG1 and its ErbB receptors, as upregulation of RAS system in the context of high levels of NRG1
results in tumourgenesis84,91. This would suggest that NF develop from SC when there is high
levels of NRG1 such as in repair SC or SCP84. Other investigations suggest that inflammation and
cytokine release by mast cells, T cells and dendritic cells during nerve inflammation may also play
a role in NF tumourigenesis upregulating proto-oncogenic transcription factors such as c-jun,
FosB and c-Fos 92. Progression to MPNST requires additional gene mutations that will not be
discussed.

1.4.2 Schwannomas
I will review the histology epidemiology, and tumourigenesis of Schwannomas.
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1.4.2.1 Histology of Schwannomas
Gross description of Schwannoma is consistent with a firm uniform rubbery tan colored lesion
with an intact capsule. Cut sections are uniform and without any significant inclusions or cystic
component93. In contrast to neurofibromas, with exception of plexiform Schwannomas, axons
are rarely present within the lesion but are often found at the periphery93.

There is a distinct

histologic pattern of Schwannomas, first described by Nils Antoni in 1920 that helps to
differentiate Schwannomas from other PNST and other spindle cell lesions. Antoni identified that
Schwannomas are composed almost entirely of SC-like cells. Within the lesion, there are two
distinct architectural patterns which he referred to as tissue type A and tissue type B that are
now referred to as Antoni A and Antoni B regions93. Antoni A regions are highly cellular, and
packed with polarized elongated spindle cells with a central bulge and tapered ends. Within
Antoni A areas, Verocay identified that cells tended to stack in rows with nuclear palisades and
alternating anuclear zones; an arrangement known as Verocay bodies94.

Verocay body

architecture is thought to be a result of SC signaling for cell-cell contact, similar to the way RSC
polarize to form bunger bands. The anuclear zone has a dense lamina rich in laminin and deficient
in other matrix components interspersed with filamentous cytoplasmic extensions95,96. The
percent of the tumour representing Antoni B regions is quite variable, and can be scant or
comprise large portions of the lesion. The Antoni B region is less cellular and does not appear to
have any apparent organization. The cells are thin and wispy separated by microcystic spaces
filled with basophilic mucin93. In some tumours, the microcystic components can convalesce to
give the appearance of a more prominent cystic component on radiological assessment97. Unlike
the Antoni A regions which are entirely composed of spindle cells, Antoni B areas often have a
high number of small vessels with hyalinized walls, and evidence of thrombosis and intralesional
hemorrhage in addition to macrophage and lymphocyte infiltration suggesting inflammation93,98.
It is also not uncommon to identify atypical nuclei, accumulation of cytoplasmic granules and
myelin debris in the Antoni B regions99. In addition to Antoni A and B, a third transitional region
between the Antoni A and Antoni B regions has been described. This transitional zone shares
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features of both Antoni A and Antoni B regions, with a dense disorganized cellular component
and a haphazard basal lamina93,94. A subset of Schwannomas can be classified as ancient
Schwannomas. These tumours demonstrate “ancient change” with an increased Antoni B
component and inclusions including: calcifications, regions of necrosis, increased nuclear atypia,
cyst formation, and xanthamatous change93. While not proven, it is accepted that the Antoni B
region represents degenerated Antoni A regions which is supported by the multiple inclusions,
cellular atypia of the Antoni B region, presence of a transitional zone, and tumour architecture
of ancient Schwannomas99.

1.4.2.2 Epidemiology of Schwannomas, with a focus on oral Schwannomas
Schwannomas (neurilemmoma) are uncommon slow growing encapsulated lesions comprised
almost entirely of neoplastic SCs in a poorly collagenized stroma and are the most common
PNST84. In contrast to neurofibromas, they tend to present at the periphery of nerves, displacing
the fascicles rather than intertwining with them84. They can occur at any site in the body arising
from cranial nerves III-XII, and autonomic or somatic nerves from the spinal nerve roots to
terminal synapse100.

Estimating the incidence of Schwannomas is difficult because the

epidemiology literature is poor. There is one report from Finland that looked at all cases of
peripheral Schwannoma from 1985 to 1995 in the Helsinki University Hospital catchment area
and found an overall incidence of 1 in 50 000 per year101.

The most common site for

Schwannomas to form is the vestibular nerve, which has an incidence of 1 in 100 000 per year102.
Approximately 25-48% of all Schwannomas are found in the head and neck region with the oral
cavity being an uncommon site representing 1% of all Schwannomas100. There is limited
published data on intraoral Schwannomas. The most common intra oral site appears to be the
tongue at 50% prevalence, with soft tissue lesions of the hard palate, soft palate, mucosa and lip
being reported25,103,104. A review of published cases of lingual Schwannoma between 1959 and
2016 identified 84 cases. The age range was between 7 and 77, with the highest incidence in the
3rd and 4th decade of life and a mean age of 28105. The average lesion size at the time of
presentation and treatment was 2.4 cm. Schwannomas were generally asymptomatic.
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Symptomatic patients reported pain, dysphagia, paresthesia, snoring and vocal changes. There
does not appear to be a gender predilection identified as cases generally are thought to occur
equally in males and females 105. Approximately 90% of all cases of Schwannomas are solitary
lesions with the remaining cases presenting as multiple Schwannomas in NF2, carney complex 1
and Schwannomatosis. Of the 3 genetic conditions, NF2 is the most common affecting 1 in 25000
births106.

Variants of Schwannomas do occur including cellular Schwannoma with higher

cellularity, plexiform Schwannomas with an infiltrative pattern, ancient Schwannomas with a
hyalinized matrix, and melanotic or pigmented Schwannomas84. Malignant transformation to
MPNST is extremely rare and seem to occur only in very large lesion, greater than 5 cm, based
on case reports107.

1.4.2.3 Cellular processes of Schwannomas tumourigenesis
Much of what we know about the cellular processes resulting in Schwannoma tumourigenesis
comes from studying patients with NF2. Patients with NF2 have a mutation in the NF2 tumour
suppressor gene, on chromosome 22 (22q12.2) which encodes for at least 10 protein variants 84.
Given the structural similarity to the protein 4.1 family ERM proteins (moesin, ezrin and radixin),
the NF2 protein is referred to as the moesin-ezrin-radixin-like protein (merlin). NF2 is inherited
in an autosomal dominant fashion with 50% of cases arising as de novo mutations84. Nonsense
and frameshift deletions do occur, but the most common mutation is single or multiple exon
deletion108. Additionally, one third of patients are mosaic for the mutation suggesting that germ
line mutation is common108. Schwannoma tumourigenesis requires either a double hit to the
native allele or more commonly loss of heterozygosity109. DNA analysis of patients with NF2
identifies a single wild type allele, while analysis of tumours cells identified two mutant copies110.
In a report on 22 cases of solitary Schwannomas, only 50% of the Schwannomas demonstrated
identifiable mutations of the NF2 gene, however merlin protein was unidentifiable on IHC and
western blot in all tumours111. This can be interpreted as either the mutation was missed during
genome sequencing due to the location of the mutation or that there are other possible
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mutations that could result in a disruption of merlin other than the NF2 gene. Patients with NF2
are prone to bilateral vestibulocochlear nerve Schwannomas resulting in profound hearing loss,
and vestibular disturbances. They also develop multiple Schwannomas in other sites of the body
with a propensity for plexiform Schwannomas84.

Other common diagnosis include the

development of meningiomas, ependymomas and retinal hamartomas84. Merlin mutations have
also been found in a variety of malignancies including colorectal cancer, prostate cancer,
melanoma and thyroid cancer suggesting that it has a function in a variety of cells outside of the
nervous system108. Nf2-/- mice models are embryonic lethal suggesting that merlin is important
for development112. Merlin is a large protein without a catalytic domain that functions to inhibit
cellular processes of proliferation, apoptosis, survival, motility, adhesion, and invasion

108,113

.

One target of merlin is p75NTR, a coreceptor with Trk receptor tyrosine kinases (TrKA, TrKB and
TrkC), sortilin and Nogo114. Cell signalling cascades of p75NTR can signal for survival or apoptosis
depending on the coreceptor it associates with115. p75NTR expression is downregulated in mature
SCs, but is substantially upregulated following axonal injury116. Rapidly after nerve injury, P75 NTR
forms a P75 NTR /TrkA complex, which activates signalling pathways that promote schwann cell
survival, dedifferentiation and proliferation117.

In the absence of reinnervation, there is a

temporally mediated switch in the coreceptors of P75NTR to sortilin. Switching of coreceptors is
thought to be influenced by SC merlin phosphorylation, as progressive merlin phosphorylation
occurs following axonal injury which corelates with switching of the P75NTR coreceptor from TRkA
to sortilin 114. In a healthy state P75 NTR /sortilin activity signals proapoptotic signals by activating
c-jun terminal kinase (JNK)113. In Schwannomas, the absence of merlin results in dysfunctional
P75 NTR signalling resulting in Schwannoma cells evading proapoptotic signals114. An alternative
theory about how Schwannoma cells survive despite proapoptotic signaling is thought to be a
result of disinhibition of the ErbB family of receptors, and other receptor tyrosine kinases, as
absence of merlin is associated with increased activity of these receptors84. A third target of
merlin is the transmembrane hyaluronic acid receptor (CD44), which mediates contact inhibition
following cell proliferation. In native repair SCs, merlin becomes phosphorylated when cell
density is low, increasing CD44 signals for cell proliferation and replication. As cell density
increases, merlin becomes hypo-phosphorylated and CD44 signalling switches to inhibit
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growth118. In Schwannomas, a lack of merlin is thought to disrupt CD44 signalling downregulating
the growth inhibition signals of CD4484. Collectively, there is a body of evidence that absence of
merlin contributes to Schwannoma cell survival and tumour growth. The function of merlin and
its target receptors is an active area of research with new targets being identified regularly.
Continued research in the field will give further clarity of merlin’s cellular function and new
insight into is role in tumourigenesis of neural and non-neural tissues. The genetic cause of
Schwannomatosis and Carney complex type 1, are less understood, but research suggests that
merlin is likely to be involved in tumourigenesis of these conditions as well84.

1.5 Immunohistochemical profile investigated
In this section I will provide a literature review of the antibodies used for immunohistochemical
(IHC) staining to investigate a possible antigen presenting cell lineage for granular cell tumours
in addition to a number of markers specific for NCCS and neuroectodermal cells that are used in
this report.

1.5.1 S100
The S100 protein family consists of a total of 24 related EF-hand calcium-binding proteins that
regulate a vast array of cellular functions. They are divided into 3 groups based on their function:
exclusively intracellular regulatory effects, exclusively extracellular regulatory effects, serving
autocrine or paracrine functions, and those that exert both intracellular and extracellular
effects119. In their active form, S100 monomers form dimers or multimers, with the monomers
classified as either alpha or beta subunits. When two alpha subunits or hands form a dimer, they
are referred to as S100A, while two beta subunits are termed S100B. When one alpha and one
beta subunit for a dimer, they belong to the S100A class of S100 proteins120. Upon calcium or
zinc binding, structural reorganization exposes protein active sites121,122. They then interact with
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a multitude of target proteins including cell surface receptors, enzymes, cytoskeleton subunits
and transcription factors to regulate cell functions including proliferation, apoptosis, assembly of
the cytoskeleton, differentiation, metabolism and cell migration119. S100 protein expression is
tightly regulated to maintain cell homeostasis. High levels of S100 expression has been identified
in neural crest cells and was once thought to have a high specificity for neural cell origin. Elevated
S100 levels has been shown to be a nonspecific marker of inflammation in a number of conditions
such as osteoarthritis123 and cardiomyopathy124 and in cancers such as, clear cell sarcoma125 and
lymphoma126 and other tumours such as chondrocytomas123 and pheochromocytoma120. S100
immunoreactivity has been identified in tumours of Langerhan cell origin while tumours of
monocyte and histocyte origin do not stain for S100. Such differences in immunoreactivity
provides utility in using S100 antibody to distinguishing Langerhans cell histiocytosis from other
histiocytosis syndromes127. S100 is a common antibody used in the diagnosis of melanoma, and
is positive in almost all cases128. While the significance of elevated S100 levels in other tumour
types is still under investigation, it remains one of the most commonly used stains to differentiate
neural crest-derived tumours from other spindle cell lesions such as myofibrosarcoma of
fibroblast lesions129. In lesions that stain positive for S100, staining with SOX10 is often used for
further differentiation of cells derived from the neural crest130. S100 has been shown to
uniformly stain cells of Schwannomas, GCTs, and the Schwann cell component of neurofibromas.
PMNST staining of S100 is seen in less than 50% of cases130. While monoclonal antibodies exist,
the most commonly used S100 stains are polyclonal and have highest affinity for S100B as was
used in this study.

1.5.2 SOX10
SOX10 is a transcription factor that has been identified as a key regulator in the differentiation
of NCCs to their terminal cell fate and plays a particularly important role in the differentiation of
mesenchymal NCCs to a glial fate55. It is generally recognized as a highly specific marker of NCC
origin in IHC studies. In a large study of 5134 human neoplasms representing all tissue types,
SOX10 was found to stain positive for all Schwann cell-derived tumours, and variably for MPNST.
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It was universally absent in all mesenchymal tumours, with the exception of rhabdomyosarcoma.
It was also absent in non-melanoma epithelial lesions, and all carcinomas with exception of basal
cell type breast cancers131. This evidence suggests that SOX10 is a valuable stain in the diagnosis
of NCC-derived tumours, specifically those derived from SCs and melanocytes. SOX10 does not
stain mature Langerhans cells There is a plethora of reports confirming SOX10 staining in GCTs
and Schwannomas12.

1.5.3 Neuron specific enolase
Enolases are metalloenzymes that convert 2-phosphoglycerate to phosphoenolpyruvate during
glycolysis. Enolases are formed from the dimerization of the subunits α, β and γ that form five
different isozymes αα, αγ, αβ, ββ and γγ in a cell specific fashion132. The γ unit forms homologous
γγ dimer or the heterogenous αγ dimer, both of which are highly expressed in neural tissues and
collectively are termed NSE133. The γγ dimer is found in highest concentrations in neurons and
the αγ dimer is higher in glial cells134. NSE has been localized to cell cytoplasm, and in
inflammation, to the cell membrane135. An additional function of NSE includes activating plasmin
from plasminogen, resulting in degradation of the extracellular matrix during inflammation such
as in tumours136.
Anti-NSE is a commonly used antibody to identify cells of a neural origin, neuroendocrine origin
and neural crest origin. Since its discovery, it has become apparent that while the expression of
NSE is mostly restricted to neural tissues in a healthy state, there is a vast array of tumours from
different cell types that stain positive for NSE. This is thought to result from the upregulation of
enolases in tumour cells by a process known as the Warberg effect (a response to hypoxia
favoring glycolysis over oxidative phosphorylation)136. Non-neural tumours that stain for NSE
include breast cancers, lung cancers, squamous cell carcinoma, renal cancers and gastric cancers.
Such tumours will often stain with other neuroendocrine markers such as secretagogin and its
theorized that the co-staining represents a tumour cell phenotype133,137. As a serology test, it is
used to identify cardiac injury, neuroblastoma from cord blood and as a marker for intracranial
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inflammation in CSF133. NSE has been shown to stain GCTs in multiple investigations1 favoring a
neural crest origin, although could also represent tumour cell inflammation.

1.5.4 Growth associated protein 43
GAP43 or neuromodulin is an intracellular growth associated protein that has a critical role in
guiding axonal growth, regulating neural cytoskeleton organization, and transduction of intraand extra-cellular growth of neurites. It is also referred to as a plasticity protein as it is induced
following nerve injury and plays a role in new synapse formation of neural networks. During
formation of new axons or regeneration of injured axons, signaling from growth ligands such as
neurotrophins and NGF or BDNF upregulates the expression of GAP43138. Newly translated
GAP43 becomes integrated in lipid rafts that are transported to the filipodia of growth cones139.
Once integrated within the cell membrane, GAP43 releases the inhibitory protein calmodulin and
bind to Ca22+ resulting in GAP43 activation via phosphorylation by protein kinase C. In its active
state, GAP43 binds to actin filaments of the cytoskeleton at the leading edge of the filipodia
providing structural connection of the cell membrane with the developing cytoskeleton139. It is
thought that as new lipid rafts are inserted at the leading edge of filipodia, membrane tension
results in elongation of the cytoskeleton; thus axonal elongation and growth cone formation are
a response to external signals rather than an intrinsic property of neurons139. GAP43 expression
is also induced during new synapse formation and is intrinsic to regions of the brain involved in
learning such as the hippocampus suggesting that its role is critical in cell membrane architecture
at synapses139.
In addition to neurons, GAP43 expression has been localized to SCPs and RSCs but not mature
SCs. It is not entirely clear what function GAP43 may have in glial cells, however in contrast to
many of the other changes that occur during dedifferentiation of glial cells expression of GAP43
occurs late at 4 weeks in RSC9. There is one report investigating GAP43 expression in rat
astrocytes. They found that following cortical injection of endotoxin lipopolysaccharide (LPS),
resulting in axonal injury, significant inflammation and astrogliosis, there was upregulation of
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GAP43 in the repair astrocytes. In vitro Astrocytes with a stellate phenotype were cultured in glial
medium and transfected with GAP43 small interfering RNA, resulting in GAP43-knockdown. The
GAP43 knockdown cells were then transferred to astrocyte conditioned medium where they
were cultured with rat cortical neurons. They identified a significant decrease in axonal spread
and the number of dendrites of the rat neurons. They also found that while GAP43 expression in
the rat neurons was preserved, there was a significant reduction in neuron GAP43
phosphorylation. There was a significant increase in expression of inflammatory markers IL-6
and TNF-α in the GAP43-knockdown group, which corresponded with increased microgliosis.
Collectively, they theorized a new role for GAP43 as a regulator of inflammation in glial cells that
is beneficial for neuronal plasticity, favoring axonal growth140.
There has been data to suggest that BPNST also express GAP43, and may be useful in diagnosing
BPNST from among other spindle cell lesions. In a recent report, GAP43 staining was positive in
MPNST, Schwannomas, NFs and desmoplastic melanomas; all other spindle cell lesions stained
negative141. Of note, GAP43 was positive in 92% of the cases of MPNST while S100 was only
positive in 62% suggesting that GAP43 may be a better tumour marker for MPNST and in turn, an
excellent marker for tumours derived from nerve sheath. GAP43 IHC has also been shown to
stain positive in cases of perineural invasion of malignancy such as Squamous Cell Carcinoma
(SCC)142. There are also reports identifying GAP43 expression in papillary thyroid cancer143 and
some non-small cell lung cancers144 and some breast cancers145. Of note, there seems to be a
significant difference in the rate of brain metastasis in GAP43 positive non-small cell lung cancers
and breast cancers when compared to cases that are GAP43 negative144,145. Additionally, breast
cancers that have metastasized to non-neural sites, such as bone, seem to be negative for
GAP43145. Such findings suggest that elevated GAP43 may preferentially facilitate tumour
metastasis across the blood brain barrier, and that differences in cancer protein expression may
play a role in determining sites of metastasis144. There are no prior reports investigating GAP43
expression in GCTs.
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1.5.5 Human leukocyte antigen – DR isotype
The human leukocyte antigen – DR isotype (HLA-DR) is a major histocompatibility complex class
II cell surface receptor that presents antigens to CD4+ T-lymphocytes during an adaptive immune
response. The adaptive immune response is too complex to review here, however I will provide
a brief summary of the events and the role of MHC class II molecules (MHC-II) in the process.
MHC-II are composed of 2 polypeptide chains, α and β that each have a peptide-binding domain,
an Ig-like domain, and a transmembrane region146. In contrast to MHC-I which are present on
the cell surfaces of all nucleated cells, MHC-II are thought to be restricted to B lymphocytes,
activated T lymphocytes and professional antigen presenting cells (APCs): monocytes,
macrophages and dendritic cells146. In response to inflammatory cytokines, APCs migrate and
phagocytize foreign material or antigens. The antigen is then processed inside the cell and
binds to MHC-II molecules forming the MHC-II/antigen complex, which is then inserted into the
cell membrane. The CD4 glycoprotein of CD4+ helper T-cells then recognizes the MHC-II
molecule and binds to the MHC-II/antigen complex activating the helper T-cell. A second signal
functions as a feedback loop in which B7 molecules (CD80 and CD86) of the APC binds to CD28
of the T-cell strengthening the activation signal. Other co-stimulating signals include interaction
of the CD40 protein of APCs and CD154/CD40 ligand of helper T-cells147. Activated helper Tcells can then further activate macrophages and activate B-cells to secrete antibodies, in
addition to activating cytotoxic T cells148.
In contrast to the general knowledge that HLA class II molecules are restricted to professional
antigen presenting cells, there is data to suggest that HLA-II can be expressed by nonprofessional
APCs. One group of nonprofessional APCs that has been shown to express HLA-DR is esophageal
epithelial cells in the disease state of eosinophilic esophagitis in response to the inflammatory
marker interferon- γ. Interestingly, other MHC-II molecules such as HLA-DP or HLA-DQ were not
expressed149. Other cell populations that can be induced to express MHC-II in response to
inflammation include liver sinusoidal endothelial cells and hepatocytes150, respiratory epithelium
and gastrointestinal epithelium151 and conjunctiva152. There are also reports identifying that
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Schwann cells can express MHC-II in inflammatory neuropathies such as guillian-barre
syndrome153 and glial cells in gliomas154. HLA-DR expression has been reported in one report on
GCTs27, and HLA-DR expression has not been reported in Schwannomas.

1.5.6 CD68
CD68 is a transmembrane glycoprotein, also known as macrosialin or scavenger receptor class D
member 1, belonging to the lysosomal-associated membrane proteins (LAMP) protein family.
LAMP proteins are found in abundance in lysosomal membranes, making up 50% of the protein
component. It is generally accepted as a marker for cells with phagocytic functions such as
histiocytes, monocytes, giant cells, Kupffer cells, and osteoclasts, and it expression is thought to
be regulated by a macrophage-specific promoter gene155,156. CD68 functions as a sorting protein
playing a role in the formation of lysosomes, exocytosis and fusion with the plasma membrane.
Lack of CD68 has been shown to result in abnormal lysosome transportation157. LAMP proteins
are thought to be in highest concentration in late endosomes and to a lesser extent cell
membranes155. CD68 has been shown to be expressed in lymphoid tissues and intestinal
neutrophils during inflammatory processes but not in a healthy state, suggesting its expression
is upregulated in permissive states158. CD68 expression has also been found in a number of
tumours arising from fibroblast and endothelial cells156 melanoma and renal cell carcinoma159.
Such evidence supports the theory that CD68 is a marker of lysosomes, rather than cells of
myeloid origin156. There is also recent evidence to suggest that non-macrophage cells have a
different gene promoter and have a slightly different protein structure due to different sites of
transcription initiation155. Anti-CD68 is well established as a IHC marker for granular cell tumours,
co-staining with the PAS-positive granules22. There is contradictory evidence on Schwannoma
CD68 staining, with some reports stating it to be strongly positive160, and other reports suggesting
it is focally positive in as few of 5% of cells, although notably as high as 85% of cells in tumours
classified as ancient Schwannomas161.
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1.5.7 CD163
CD163 is a hemoglobin scavenger receptor thought to be

relatively specific marker for

macrophages, and a high CD163 expression occurs during macrophage activation in an
inflammatory processes162. CD163 scavenges the hemoglobin-haptoglobin complexes and to a
lesser extent, free hemoglobin, allowing for endocytosis and intracellular degradation of the
inflammatory substrate indirectly serving an anti-inflammatory role163. More recently, additional
roles of CD163 have been identified including immunomodulating effects via cell signal cascades
following binding to viruses and bacteria, and functioning as a receptor for tumour necrosis factor
(TNF), a weak contributor to apoptosis signals. CD163 has also been shown to be shed by cells
exerting anti-inflammatory effects164. A recent report identified that glial cells and neurons can
be induced to express CD163 following intracranial hemorrhage165.

CD163 expression in

Schwannomas and GCTs has not been investigated.

1.5.8 CD40
CD40 is a costimulatory protein found on the cell surface of professional APCs during an innate
immune response and a member of the TNF-receptor superfamily. During the activation of CD4+
T cells, CD40 of APCs binds to CD154/CD40 ligand of helper T cells enhancing the activation of
helper T cells. CD40 is also present on the cell surface of B cells, and ligating of B-cell CD40 with
activated T-cell CD154 plays a role in class switching of memory B cells downstream of T cell
activation. CD40 is also expressed by a number of cell types including epithelial cells, smooth
muscle cells, fibroblasts and endothelial cells in inflammatory states166. Data of CD40 expression
by GCTs and Schwannomas has not been reported.

1.5.9 CD11c
CD11c is an integrin alpha X chain protein that is thought to be highly expressed by macrophage,
dendritic cells and leukocytes, although most widely thought to be a marker for myeloid dendritic
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cells167. It is thought to primarily function as a fibrinogen receptor, playing important roles in
monocyte adhesion and chemotaxis. It also functions as complement receptor 4 mediating
phagocytosis of inactivated C3b particles, and has a poorly defined role in the innate immune
response168. CD11c expression has not been investigated in GCTs or Schwann cells.

1.6 Quantitative polymerase chain reaction profile
I also used reverse transcriptase-quantitative polymerase chain reaction (RT-qPCR) to detect
select transcripts in GCTs. Specifically, we investigated genes expressed by NCCs and SCs. In this
section I will review the target genes, SOX2, SOX9, Nestin, GFAP, and Tubulin-3. SOX10, CD68
and NF2 will also be investigated but already been discussed earlier in the report

1.6.1 SOX2
SOX2, sex determining region Y box 2, is a transcription factor that is variably expressed by NCC
and SCs. It is known as a master transcription factor due to its role in embryonic stem cells
promoting pluripotency, and self-renewal of stem cell populations169. SOX2 expression is not a
hallmark of any mature cell line and its expression varies according to cell maturity with higher
levels of SOX2 transcription factor thought to represent less differentiated or more embryoniclike cells170 In the context of SCs, SOX2 functions to inhibit the induction of Krox20 58, effectively
promoting a less differentiated cell stage. Cell maturation causes reduced SOX2 and activated
Krox2058. A reverse process likely occurs following nerve injury, whereby SOX2 expression is
upregulated, and Krox20 is inhibited as SCs have been shown to express SOX2 after nerve injury
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. In summary, SOX2 has been found to be upregulated in SCP and RSCs but downregulated in

both NCCs and absent in mature SCs with SOX2 functioning like a molecular rheostat for cell line
maturity169. Another role of SOX2 in NCC populations is to inhibit early SCPs or NCCs from
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developing into a melanocyte cell by inhibiting micropthalmia-associated transcription factor
(MITF), a master regulator of melanocyte development, function and survival172. Recently, there
have been a number of cancers identified including SCC and small cell lung cancers that express
SOX2, with SOX2 transcription factor levels correlating with tumour aggression and worse
prognosis173. If GCTs are found to express SOX2 mRNA, this would support an early SC stage or
possibly repair SCs as the cell of tumourigenesis.

1.6.2 SOX9
SOX9 is recognized as being a relatively non-specific transcription factor that functions during
development of all 3 germ cell layers. Like other SOX proteins, its function is dependent on
forming complexes with other transcription factors and post-transcriptional changes that can
have context-specific effects for promotion or inhibition of target gene translation174. Based on
the amino acid sequence of the HMG domain, SOX9 can be grouped with SOX8 and SOX10 into
the SOXE subgroup, which share similar functional properties175. SOX9 expression persists in
many different cell types derived from both the ectoderm and endoderm at variable levels. In
the context of neural crest cell, SOX9 is a target of sonic hedgehog, and is essential for the initial
formation of the neural crest174. SOX9 also seems to play a supporting role in promoting SCP and
their maturation to myelinating SCs as it is not sufficient to promote myelination in SOX10
knockout mice but is reported to have a role in mature SC survival174. SOX9 gene is reported to
be upregulated in neurofibromas, and in MPNST relative to native SCs. In contrast, IHC studies
identify Schwannomas to either stain negative for SOX9 or focally and weakly, suggesting that
SOX9 may actually be a useful marker for NFs174. SOX9 is an excellent marker for early NCCs, its
function and expression in mature cells can be variable. There is evidence to suggest that its
expression is upregulated in NF but downregulated in Schwannomas. IF GCTs express SOX9
mRNA it would mostly support a dedifferentiated NCC cell phenotype.
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1.6.3 Nestin
The neuroectodermal stem cell marker (Nestin) is a subunit of type IV intermediate filament and
is coded by the NES gene. Nestin is generally believed to be expressed by immature cells during
cytoskeleton formation, particularly by axons of the PNS and skeletal muscle. As cells mature,
Nestin is replaced by cell specific intermediate filaments such as GFAP in glial cells. Nestin
expression is also reported to be upregulated following glial cell dedifferentiation in response to
neuron injury176. Nestin has been found to stain positive for GCTs and Schwannomas on IHC177.
Given the IHC data, we would expect GCTs to express mRNA for Nestin.

1.6.4 GFAP
Glial fibrillary acidic protein is a type III intermediate filament protein coded by the GFAP gene.
GFAP is thought to be expressed by all glial cells of the nervous system at some point during
cellular maturation. Levels of GFAP remain high in the glial cell of the central nervous system
such as astroctyes, while the predominant cytoskeleton components of mature peripheral glial
cells is vimentin59. In SCs, GFAP expression is inducible upon cell dedifferentiation178. IF GCTs
are found to express the GFAP mRNA, it would suggest that GCTs arise from immature SC lines.

1.6.5 Beta Tubulin-III
Beta-tubulin-III is one of seven B-tubulin isotype proteins, that belong to the microtubule family,
and is coded by the TUBB3 gene179. It is expressed exclusively in cells of the nervous system while
other subtypes are thought to represent other cell types180. β-Tubulin-III is found in highest levels
in neurons during cellular differentiation and growth, and lower levels at cellular maturity. There
are a number of neuroblastic tumours which have high levels of β-Tub3 such as retinoblastoma
or medulloblastoma179. In addition to a number of neural derived tumours, non-neural tumours
expressing β-Tub3 include adrenal pheochromocytoma and breast cancer180. Glial cells are
thought to not express β-tubulin. IF β-Tub3 mRNA is detected it would suggest that there was
neural tissue present within the selected tissue, confounding the results of the specimen.
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Chapter 2
2 Hypothesis and Rational
2.1 Hypothesis
We hypothesize that granular cell tumours exhibit an antigen presenting cell phenotype and are
derived from Schwann cells. To test our hypothesis, we utilized IHC to examine GCT and
Schwannoma immunoreactivity to APC-associated markers. We expected there to be significant
differences between the IHC staining profiles of Schwannomas and GCTs, providing evidence that
while they may originate from a common cell type, they express different phenotypes. We also
performed qPCR to detect select gene transcripts to bolster our IHC findings.

2.2 Rationale
The current understanding is that GCTs represent a tumour originating from SC lineage, although
a number of different cell types have been considered as the cell of origin for GCTs including
myoblasts1, fibroblasts17, Schwann cells1, histiocytes18 and endomesenchymal cells12. A SC
lineage is supported by the similarity of IHC profile for markers of neural crest cells and
neuroectodermal origin including SOX10, S100 and NSE. SOX10 seems to be a stronger tumour
marker for NCC origin compared to S100130. NSE is now considered to be much less specific than
we originally thought, as NSE seems to be restricted to healthy neural tissue, but is induced
during tumourigenesis accounting for the increased energy demands and reliance of glycolysis as
an energy source133.

One significant difference between the IHC profile of GCTs and

Schwannomas previously reported is their staining for CD68, with GCTs staining strongly and
diffusely, and Schwannomas staining weakly and in only a small number of cells within the lesion.
Staining of CD68 a lysosomal marker supports a possible APC phenotype. Additional evidence
that the granular appearance of GCTs results from the accumulation of lysosomes is supported
by work identifying mutations of the gene coding for accessory proteins of H+-ATPase , ATP6AP1
and ATP6AP2 providing evidence of the abnormal lysosome content of the granular cells 36. The
finding of a genetic mutation of GCTs suggests that the GCTs are true tumours and not reactive
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lesions. The serendipitous discovery of HLA-DR staining of a GCT in our lab, during a study of
Langerhans cell lesions of the tongue, provides additional support of an APC phenotype for GCTs.
An APC phenotype could suggest that GCTs that have undergone a mesenchymal transformation.
Testing our hypothesis would further our understanding of this rare and unusual tumour.
Additional IHC stains could also aid in histological diagnosis of GCTs and separation from other
lesions with a granular cell appearance.

2.3 Aims and objectives.

1) Investigate an APC phenotype of GCT using immunohistochemistry. We will use a number
of different antibodies to detect antigens associated with an APC phenotype, including
HLA-DR, CD68, CD163, CD40 and CD11c.
2) Investigate a possible NCC origin of GCTs by detecting GAP43 immunoreactivity, in
addition to S100, SOX10 and NSE.
3) Detect mRNA of Nestin, SOX2, SOX9, SOX10, NF2 and GFAP to assess level of cell maturity.
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Chapter 3
3.0 Material and Methods
In this chapter I will review the methods employed in this investigation to explore an APC
phenotype for GCTs using IHC techniques, and the NCC developmental phenotype of GCTs using
RT-qPCR.

3.1 Case Selection
The pathology database of the Division of Oral Pathology, in Pathology and Laboratory Medicine
of Schulich School of Medicine & Dentistry, Western University, was used to identify a total of 23
serial cases of benign GCTs from 2006-2016. Malignant cases were included. An additional 10
cases of Schwannoma were randomly selected from the database over the same time interval to
be used as tissue control. We did not identify any instance of two separate GCTs biopsied in the
oral cavity of the same individual. In the instance of the same lesion biopsied on more than one
occasion, with an incisional biopsy followed by an excisional biopsy, the lesion was treated as a
single case. Once cases were identified, we verified the availability of the Formalin-fixed, paraffinembedded tissue specimens (FFPE) in the tissue archives and assessed that there was sufficient
material for the completion of our proposed experiments. Confirmation of the histopathological
diagnosis was made using H&E sections and light microscopy by the graduate student and an
experienced Oral Pathologist (supervisor). Patient information collected included age, sex, and
location of the lesion biopsied. Tables 1.1 and 1.2, summarize the demographic information for
the 23 GCTs and 10 Schwannomas.
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Table 1.1 Demographics and site of biopsy for Granular Cell Tumours

Case No.

Age

Sex

Site

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23

41
33
15
43
20
36
48
50
37
55
39
21
52
48
46
35
63
55
37
21
56
58
43

Female
Female
Female
Male
female
Male
female
Male
female
female
female
female
male
male
male
female
female
female
male
female
male
male
Female

midright dorsum of tongue
dorsum of tongue
dorsum of tongue
dorsum of tongue
right tongue
dorsum of tongue
left posterior hard palate
dorsum of tongue
left lateral border of tongue
right palatal mucosa
dorsum of tongue
right dorsum of tongue
right lateral border of tongue
right dorsum of tongue
right dorsum of tongue
right dorsum of tongue
left dorsum of tongue
left dorsum of tongue
dorsum of tongue
right lateral border of tongue
dorsum of tongue
right lateral ventral tongue
left dorsal tongue
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Table 1.2 Demographics and site of biopsy for Schwannomas.

Case No.

Age

Sex

Site

1
28
Male
buccal mucosa 37
2
21
Male
left dorsum of tongue
3
23
Male
right tip of tongue
4
41
Male
left buccal mucosa
5
16
Female
*** oral cavity
6
37
Female
lower lip mucosa
7
22
Male
lower lip mucosa
8
15
Male
left buccal vestibule
9
16
Male
dorsum of tongue
10
31
Male
Upper lip
*** site of biopsy was unspecified, anatomically from the oral cavity

3.2. Immunohistochemistry
GCTs and Schwannomas were stained for neural markers: S100, SOX10, NSE and GAP43; APC
markers: HLA-DR, CD68, CD163, CD40 and CD11c. IHC for these antigens was performed at the
London Health Sciences Centre, London Ontario, using Dako Autostainer Link 48. IHC staining for
GAP43, CD40 and CD11c was completed in our laboratory at the Department of Pathology and
Laboratory Medicine, Schulich School of Medicine & Dentistry, Western University. Sections
processed by the University Hospital Pathology Laboratory. Table 2 provides a summary of the
IHC antibodies used in this investigation.
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Table 2. Summary of the IHC antibodies applied to the GCTs and Schwannomas

Antibody Manufacture/
Cat#

Antibody
type

Constituent tissue and Labelling Dilution
Targets

S100

Dako, Santa Clara CA
IR50461-2
Dako, Santa Clara CA
!R61261-2
Santa Cruz Biotech,
Dallas TX, sc-365692
Bio-Techne Canada,
Oakville On, NB300143

rabbit
polyclonal
mouse
monoclonal
mouse
monoclonal
rabbit
polyclonal

Neural tissues, S100B (strong) S100A1
and S100A6 (weak)
Neural tissues, γ-enolase subunit

Automated

Neural tissues, SOX10 transcription
factor
Regenerating neural tissues/growth
cones, GAP43 intracellular growth
protein/membrane protein

Automated

Dako, Santa Clara CA
MO74601
Dako, Santa Clara CA
GA61361-2
Vector laboratories,
Burlingame CA
VP-C374

Mouse
monoclonal
Mouse
monoclonal
Mouse
monoclonal

APCs and lymphocytes, Alpha-chain of
HLA-DR cell surface receptor
Macrophage,
lysosomal-associated
membrane proteins
Macrophage,
hemoglobin-scavenger
receptor

Automated

Abcam, Toronto ON,
ab13545
Abcam, Toronto ON,
ab52632

Rabbit
polyclonal
Rabbit
monoclonal

APCs, cell surface innate immune
response costimulatory protein
APCs, cell surface fibrinogen receptor

1/1000

NSE
SOX10
GAP43

HLA-DR
CD68
CD163

CD40
CD11c

Automated

1/5000

Automated
Automated

1/300

3.2.1 Slide preparation
Five μm tissue sections of each case were cut from FFPE blocks using a microtome (Microm HM
325;GMI Inc., Ramsey, MN). Tissue sections were then transferred to a warm water bath and
mounted onto positively-charged glass slides. The slides were left to dry overnight in an
incubator at 37°C.

3.2.2 IHC staining protocols for GAP43, CD40 and CD11c
Sections of GCTs and Schwannomas, in addition to appropriate positive controls (Schwannoma
for GAP43 and tonsil for CD40 and CD11c) and negative case controls, were used. The sections

39

were hydrated using standard serial ethanol gradient. Endogenous peroxidase activity was
quenched with 3% hydrogen peroxide in methanol. Antigen retrieval was performed in citrate
buffer (pH6) using a decloaking chamber (Biocare Medical, Pacheco, CA ). The temperature
profile used included 112.5°C for 90 seconds, then 90°C for 10 seconds. Sections were cooled
using running tap water and then washed for 5 minutes in Phosphate-buffered Saline (PBS).
Sections were placed in a humidified chamber and were blocked for 30 minutes with 2.5% horse
serum. After 30 minutes, the horse serum was drained and primary antibodies were applied.
Rabbit anti-human Gap43 antibody (cat no. NB300-143, Bio-Techne Canada Corporation,
Oakville, ON) was applied at a 1/5000 dilution. Rabbit anti-human CD40 antibody (cat no.
ab13545, Abcam, Toronto ON) was applied at a 1/1000 dilution. Rabbit anti-human CD11c (cat
no. ab52632, Abcam, Toronto ON) was applied at a dilution of 1/300. Slides were incubated
overnight at 4°C. Negative control included incubation of slides in 2.5% horse serum alone (no
primary antibody).
The next day, sections were washed 3 times for 3 minutes each in PBS and then incubated with
secondary antibody.

ImmPRESS anti-Rabbit IgG peroxidase (cat No. VECTMP540150, MJS

Biolynx, Brockville,ON) was used for GAP43 and CD11c detection for 30 minutes at room
temperature. Avidin-Biotin Complex VECTASTAIN Elite ABC-HRP Kit (cat no. PK-7200, Vector
Laboratories, Burlington, ON, Canada) was used for CD11c at room temperature for 30 minutes.
Sections were then washed 3 times for 3 minutes each in PBS. To visualize the staining, sections
were incubated with a 3,3'-Diaminobenzidine (DAB) peroxidase substrate kit (cat no VECTSK4100,
MJS Biolynx, Brockville,ON) for up to 10 minutes. The sections were counterstained with Harris
hematoxylin (Leica Biosystems Inc, Concord, ON). Sections were dehydrated through ascending
alcohols, cleared with xylene and cover slipped using Cytoseal (Fisher Scientific, Toronto, ON) for
microscopic examination.
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3.3 Evaluation of immunostaining
All slides were examined under light microscopy and scored according the semiquantitative
methods described below. In addition to manual scoring, 5 randomly selected cases of both GCTs
and Schwannomas for the antibodies GAP43, CD68, HLA-DR, CD163, were subjected to digital
analysis using QuPath.

3.3.1 Manual IHC scoring
Each IHC slide was evaluated under light microscopy by the graduate student author and an
experienced Oral Pathologist utilizing a semiquantitative analysis described below. The negative
and positive control sections were compared to their study section to ensure that DAB staining
of the sections was representative of the primary antibody IHC target. During the manual scoring
of granular cells, only the large polygonal cells that matched the histological description of the
granular cells of GCTs were assessed. Regarding Schwannomas, given the presence of a capsule,
analysis was restricted to spindle shaped cells within the capsule. The scoring criteria consisted
of an objective analysis of the average number of cells that stained positive within representative
high-powered fields for the given section. Staining intensity was subjectively scored relative to
the appropriate positive controls. The scoring system used in this investigation are illustrated in
Table 3.1 and 3.2.

Table 3.1 Staining Intensity. Semiquantitative scoring values for identifying stain intensity of
GCTs and Schwannomas, relative to positive controls
Score

Staining intensity

0
1
2
3

Absent
Weak
Moderate
High
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Table 3.2 Percentage of cells stained. Semiquantitative scoring values for identifying the percent
of cells staining positive within representative high-powered fields

Score

Percent positive staining

0
1
2

0%
0-50%
>50%

3.3.2 IHC digital analysis.
Five cases of GCTs and Schwannomas underwent high resolution whole-slide imaging using the
Aperio slide scanner at the Department of Pathology and Laboratory Medicine, London Health
Science Center for GAP43, HLA-DR, CD163 and CD68. Images were then uploaded to QuPath
(v0.1.2), a validated open source software for bioimage analysis. Images stained with the same
IHC antibody (5 cases of GCT and 5 cases of Schwannoma) were grouped to create a multi-slide
project. For each of the four multi-slide projects, the same workflow was followed. Pixel size of
all images was verified to be less than 0.5x0.5 μm ensuring that images were of adequate
resolution for analysis. Image type for all images was set to Brightfield (H-DAB). The polygon
tool was then used to accurately trace the boundaries of the lesion/region of interest, defining
an object for analysis for each image. A representative image was then selected to perform color
deconvolution, setting the stain vectors for Hematoxylin, DAB, and the background. Automated
cell detection was completed by identifying cell nuclei, via the hematoxylin optical density and
nucleus size parameters. The cells boundaries were digitally determined via cell expansion
parameters, relative to the nuclei of the cells in proximity. Positive cell detection was determined
by the mean DAB optical density of the cell. A detection classifier was trained by adjusting the
DAB optical density classification for low, medium and high intensities after visually selecting cells
that had objectively low, medium and high staining intensities as a reference. The workflow for
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the representative image was then used to write a script that was applied to all images in the
multi-slide project. Data from cell detection was reported as percentage of cells detected and as
an H-score. H-scores range from 0-300 and are calculated by 3x percentage of strong staining +
2x percentage of moderate staining + 1x percentage of weak staining (total ranging from 0 to
300).

Figure 1. Select images taken from QuPath digital file of GCT Case# 1. Immunoreactivity of antiHLA-DR antibody detected by DAB optical density (brown color), counterstained with
haematoxylin. Indeterminate magnification. a) demonstrating the object for cell detection
defined by the red border. b) Demonstrating positive cell detection stratified by mean DAB
optical density, blue= negative, yellow= low intensity, orange = medium intensity and red = high
intensity.

a)

b)
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3.4 Statistical analysis of IHC results using semiquantitative and QuPath
Given that percent cells stained and stain intensity are both ordinal variables, a linear-by-linear
association test was completed to assess for the correlation of the two variables between the
pooled GCT and Schwannoma data resulting in a near perfect correlation. Due to the high level
of correlation, only stain intensity was used for further statistical analysis, and results comparing
staining intensity between GCTs and Schwannomas can be extrapolated to the percentage of
cells staining. A Cochrane-Armitage test for trend using a generalized chi-squared test was used
to compare the overall staining intensities for GCTs vs Schwannomas and for the 9 IHC antibodies
used in this study with the ordered nominal variable (intensity) and a non-ordered nominal
variable cell type. As multiple hypotheses were applied to the same data set, we applied a
Bonferroni correction. Three of the IHC stains (S100, CD40 and CD11c) had no variability within
their data set and were of equal values between GCTs and Schwannomas – these were not used
when calculating the Bonferroni correction with m=6 ( αbonferroni =0.5/6)
Using the data generated by digital analysis, student t-tests, and Welch’s t-test correction were
performed to asses for differences between the H-scores of GCTs and Schwannomas. Again, a
Bonferroni correction was used with m=4 (αbonferroni 0.5/4). We also completed a Pearson
correlation coefficient test, comparing the H-scores and the staining intensity for each individual
IHC antibody.

3.5 Protocol for RT-qPCR
In this section, I will describe the protocols used for extracting RNA from FFPE tissues, the
synthesis of cDNA from RNA, and methods for RT-qPCR to detect reactivity of CD68, Nestin, SOX2,
SOX9, SOX10, NF2, GFAP, and β-Tub3.
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3.5.1 Tissue preparation
Eleven FFPE blocks were assessed to have sufficient tumour material to proceed with RNA
extraction. Tissue H&E was examined under light microscopy to identify a region of the tumour
that demonstrated typical features of GCTs, and all attempts were made to exclude any nontumour cells. The region of interest was marked on the H&E slide using a marking pen, and we
identified the corresponding site of the FFPE block and obtained a 1 mm punch biopsy at a depth
of 1mm. The tissue plug was then placed into 1.5 mL collection tube. We verified that the site
of the punch biopsy was representative of the tumour by obtaining 5 μm tissue sections, of each
respective case, from hydrated FFPE blocks using a microtome. H&E staining of these sections
were completed, and the sections were visualized under the microscope confirming the accuracy
of the tissue punches to be restricted to tumour tissue in all 11 cases.

3.5.2 Deparaffinization of tissue
Paraffin was removed from the specimens using the following procedures. First Xylene was
added to the collection tubes, agitated on a vortex mixer (3 times for 4 seconds), and incubated
for 2 minutes. The tubes were spun at 12000 x g for 2 minutes. The supernatant was discarded
and the steps were repeated 3 times.

We then repeated the process using 70% ethanol.

Supernatant was removed from the tube and the tissue was incubated for 15 minutes at 55°C to
ensure that the tissue plugs were dry.

3.5.3 RNA isolation
RNA isolation was completed using the High Pure FFPE RNA Micro Kit (Roche Applied Sciences,
Mannheim, Germany, Cat # 04823125001). Tissue lysis buffer and 10% sodium dodecyl sulfate
were added to the tissue plugs, followed by protein kinase K solution. Tubes were then agitated
and incubated at 55°C for 3 hours. The cell lysate was extracted and placed into a RNA binding
spin column. Each tube was then spun and the flow-through was discarded. DNase solution was
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added, and the tubes were allowed to incubate 15 minutes at room temperature. Total RNA was
then purified by rinsing the spin columns with a series of buffer solutions, centrifuging at 8000 x
g for 5 minutes and discarding the supernatant each time. Elution buffer was added and allowed
to incubate at room temperature for 1 minute. The RNA spin column was then centrifuged at
8000 x g for 1 minute. The RNA eluate was collected and used for RNA quantification.

3.5.4 RNA quantification
RNA concentration of the RNA eluate was measured using the Qubit Quan-iT RNA BR assay kit
(Thermo Fisher Scientific Carlsbas, CA, USA, cat # Q10210) and Qubit Flurorometer. Qubit RNA
BR reagent was diluted to 1:200 in Qubit RNA BR buffer. A total of 198 µL of prepared Qubit
working solution and 2 µL of RNA eluent were added to clear 0.5 mL tubes. An additional 2 tubes
were prepared by adding 10 µL Qubit standards to 190 µL of working solution and were used to
calibrate the fluorometer to the standards. Concentration of RNA was then referenced to the
prepared standards. RNA concentration in µg/mL was determined using the formula [QF =
fluorescence reading]:
RNA concentration = QF * (200/μL sample added)

3.5.5 cDNA synthesis and RT-qPCR
In our study, 6 of 11 samples yielded sufficient RNA to proceed with complimentary DNA (cDNA)
synthesis. Isolated RNA was transcribed to cDNA using the iScript cDNA Synthesis Kit (Bio-Rad
Laboratories, Inc., Hercules, CA, Cat # 1708890). For each sample, 20 µL of cDNA mixture was
prepared (4 µL 5x iScript reaction mix, 1 µL iScript reverse transcriptase, 100 ng RNA and balance
of the volume as nuclease free H2O). RT-qPCR reactions were carried out in 96 well arrays (HardShell® Low-Profile Thin-Wall 96-Well Skirted PCR Plates, Bio-Rad, HSP-9601). Each well contained
10 µL RT² SYBR Green qPCR Mastermix (Bio-Rad, 330501), 2 µL primer (primer information in
Table 4), 1 µL cDNA mix and 7 µL nuclease free water. We also used a No Template Control (NTC),
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which contained 8 µL of nuclease free water, and no cDNA. The array was constructed with case
# as the Y axis and RT-qPCR was completed over a total of 40 cycles of amplification. qPCR was
performed in Bio-Rad CFX Connect. β-actin was used as housekeeping gene. Data was analyzed
by DDCT method using CFX Manager (Bio-Rad Laboratories).
Table 4. Summary of primers employed in RT-qPCR
Gene Assay

Vendor

Cat #

CD68
NESTIN
SOX2
SOX9
SOX10
NF2
GFAP
Beta-Actin
Beta- TUB3

QIAGEN
QIAGEN
QIAGEN
QIAGEN
QIAGEN
QIAGEN
QIAGEN
QIAGEN
QIAGEN

QT00037184
QT01015301
QT00237601
QT00001498
QT01670326
QT00030191
QT00081151
QT01680476
QT00083713

Amplicon
Length
73 bp
75 bp
64 bp
111 bp
145 bp
148 bp
96 bp
104 bp
78 bp
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Exon-spanning
Y
Y
N
Y
Y
Y
Y
Y
Y

CHAPTER 4
4.0 Results:
In this section, I will review our interpretation of the results obtained in the investigation of an
APC phenotype using IHC techniques and a NCC developmental phenotype using RT-qPCR.

4.1 Demographics
The mean age for patients diagnosed with a biopsy-confirmed GCT was 41.4 ± 13.1. GCTs were
most prevalent in the 4th-6th decades of life with 6 cases diagnosed in the 4th and 5th decade and
7 in the 6th decade (Figure 2.1). The mean age for patients with a biopsy proven Schwannoma
was 25 ± 9. Lesions were most prevalent in the 3rd decade of life.

Figure 2.1 Distribution of patient age at the time of biopsy for GCTs and Schwannomas
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There were 14 cases of GCTs in females and 9 in males with a female:male ratio of 1.56:1 (Figure
2.2). There were 8 cases of Schwannomas in males and 2 in females with a male:female ratio of
4:1.

Figure 2.2 Sex distribution for GCTs and Schwannomas

16
14

Number of Cases

12
10
8
6
4
2
0
GCTs

Schwannomas
Male

Female

Incidence of anatomic location within the oral cavity are demonstrated below (Table 5.1 and 5.2).
The most common location for GCTs was the dorsal tongue with 16/23 lesions or 69.5% of cases.
There was no obvious anatomical site predilection for Schwannomas.

Table 5.1 Summary of anatomic location of GCTs

Anatomical site

Incidence

Dorsum of tongue
Lateral tongue
Ventral tongue
Hard palate
Soft palate

16
4
1
1
1
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Table 5.2 Summary of anatomic location of Schwannomas
Anatomical site
Buccal mucosa
Dorsum tongue
Lateral tongue
Lip
Undisclosed oral cavity

Incidence
3
2
1
3
1

4.2 Qualitative evaluation of GCTs and Schwannomas
In this section, I will review the objective findings of each antibody employed in this investigation
for both GCTs and Schwannomas.
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4.2.1 Qualitative evaluation of S100 staining
S100 immunoreactivity was identified in both cytoplasm and nuclei of cells in GCTs and
Schwannomas, although nuclear staining appeared to be greater than that of cytoplasm (Figure
3). Of note, when examining the spindle cells of Schwannomas, the staining was more punctate
with bands of higher staining intensity in direct proximity to the nucleus, while cytoplasm staining
of GCTs was more diffuse. Objectively, nearly all granular cells of GCT, and spindle cells of
Schwannomas were found to stain positive with little to no variability in the staining intensity of
positively staining cells.
Figure 3. Immunohistochemical reactivity of S100 in GCTs and Schwannomas.
Immunoreactivity was detected by DAB (brown colour). Images were taken using 200x original
magnification. a) GCT stained with high intensity and diffusely in all cells, b) Schwannoma stained
with high intensity in all cells with a punctate appearance

a)

b)
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4.2.2 Qualitative evaluation of NSE staining
Objectively, there was a difference in the staining of NSE immunoreactivity between GCTs and
Schwannomas. Staining of GCTs was restricted to the cytoplasm, while Schwannomas were found
to have mostly cytoplasm staining although nuclear staining was seen in many cells (Figure 4).
Nearly all GCT granular cells were found to stain positive and with high intensity. Within a given
granular cell, no identifiable architecture could be identified but there were patchy regions that
stained with higher intensity that the remainder of the cytoplasm. Most spindle cells of
Schwannomas were found to stain positive, although cells with absent immunoreactivity were
identified, certainly more than 50% of cells stained positive in all cases. In cases of Schwannoma
that stained with medium intensity, the level of staining was relatively the same for all cells that
stained positive in a given section. There was no architectural pattern of staining identified for
the spindle cells.
Figure 4. Immunohistochemical reactivity of NSE in GCTs and Schwannomas.
Immunoreactivity was detected by DAB (brown colour). Images were taken using 200x original
magnification. a) GCT stained with high intensity in the majority of cells B) Schwannoma stained
positive with weak to moderate intensity in >50% of cells

a)

b)
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4.2.3 Qualitative evaluation of SOX10 staining
SOX10 immunoreactivity was restricted to the nucleus of GCTs and Schwannomas (Figure 5).
Staining was of high intensity for all cells, and there was almost no variability in the staining
intensity of cells in the same section. There was some background blushing that was seen on the
Schwannoma sections, but not the GCTs, however it did not impact our analysis. There was one
section of GCT, case #21, that had no immunoreactivity for SOX10 (data not shown). Given that
all other cases stained with high intensity in almost all cells, we repeated IHC staining for case
#21. Negative reactivity was also seen on the second section processed (data not shown). It
should be noted that this section had freeze artifact, however immunoreactive staining for all
other antibodies on this section were nearly identical to other sections for that particular
antibody.
Figure 5. Immunohistochemical reactivity of SOX10 in GCTs and Schwannomas.
Immunoreactivity was detected by DAB (brown colour). Images were taken using 200x original
magnification. a) GCT, nucleus stained with high intensity in all cells b) Schwannoma, nucleus
staining with high intensity in all cells

a)

b)
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4.2.4 Qualitative evaluation of GAP43 staining
Objectively there was a difference between the immunoreactivity of GCTs and Schwannomas
(Figure 6.1 and 6.2). Both GCT and Schwannoma immunoreactivity was found to be restricted to
the cytoplasm. There was considerable variability in the staining intensity of the cells both when
comparing sections of the same tumour and when comparing positive cells from the same section
for both GCTs and Schwannomas. For GCTs, two different cell staining patterns were identified.
Cells either stained mostly diffusely with sparse punctate staining, or cells stained mostly with a
punctate pattern, and minimal diffuse cytoplasmic staining. Within a given section, granular cells
tended to either demonstrate more punctate or more diffuse staining patterns. Staining of the
Schwannomas was considerably different than that of GCTs.

All positive spindle cells

demonstrated diffuse cytoplasmic staining and a punctate pattern was not appreciated. Spindle
cells found in the densely populated Antoni A areas were found to stain with high intensity. In
contrast, the spindle cells of the Antoni B areas were either negative for GAP43 reactivity or
stained with low to moderate intensity in less than 50% of the cells. This gave a patchy
appearance to the Schwannoma GAP43 sections. During our semiquantitative analysis, sections
with a higher percentage of Antoni A areas, relative the their Antoni B areas, scored higher than
sections with a higher percentage of Antoni B relative to Antoni A areas. An unexpected finding
was localized staining of some epithelial cells of the stratum basale, and blushing of the stratum
spinosum was also seen for nearly all cases.
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Figure 6.1 Immunohistochemical reactivity of GAP43 in GCTs and Schwannomas.
Immunoreactivity was detected by DAB (brown colour). Images were taken using 200x original
magnification. a) GCT, stained with high intensity in all cells, mixed diffuse and punctate staining.
B) Schwannoma, Antoni A regions stained with high intensity with a diffuse appearance, while
Antoni B was weak or absent

a)

b)

Figure 6.2 Immunohistochemical reactivity of GAP43 in Schwannomas.
Immunoreactivity was detected by DAB (brown colour). Image was taken using 20x original
magnification. Antoni A regions stained with high intensity, while Antoni B stained with low
intensity or negative staining
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4.2.5 Qualitative evaluation of HLA-DR staining
Both GCTs and Schwannomas has similar staining for HLA-DR immunoreactivity (Figure 7).
Staining was mostly restricted to the cytoplasm, with some nuclei appearing to stain positive for
GCTs. Staining patterns were punctate on a diffuse background for both tumours. Nearly all
granular cells of GCTs and spindle cells of Schwannomas stained positive with a high intensity,
and there was minimal variability when comparing sections or cells of the same section for both
tumours.
Figure 7. Immunohistochemical reactivity of HLA-DR in GCTs and Schwannomas.
Immunoreactivity was detected by DAB (brown colour). Images were taken using 200x original
magnification. a) GCT stained with high intensity and diffuse appearance B) Schwannoma stained
with high intensity and diffuse appearance

a)

b)
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4.2.6 Qualitative evaluation of CD68 staining
There were considerable differences in the staining of CD68 immunoreactivity for GCTs and
Schwannomas (Figure 8). Staining was restricted to the cytoplasm of both tumours. GCTs were
found to stain with a punctate pattern on a light diffuse cytoplasmic background. All cells had
similar staining intensity, both when comparing cells of a given section or when comparing
section. Schwannoma staining was variable. One section was void of any appreciable staining
for CD68 immunoreactivity. The other 9 sections had low to moderate staining. Some cells
identified as positive had as few as one appreciable granule of staining, while other cells had
more of a diffuse cytoplasm reactivity.
Figure 8. Immunohistochemical reactivity of CD68 in GCTs and Schwannomas.
Immunoreactivity was detected by DAB (brown colour). Images were taken using 200x original
magnification. a) GCT stained with high intensity in all cells with a diffuse appearance. B)
Schwannoma staining was negative

a)

b)
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4.2.7 Qualitative evaluation of CD163 staining
Schwannomas were found to stain positive for CD63 with a high intensity in all sections, while
GCT immunoreactivity was absent (Figure 9). Schwannoma staining was punctate for all cells,
and staining was restricted to the cytoplasm. The number of granules varied between cells, but
the majority of cells stained positive. On examination of the GCT sections, a number of cases
demonstrated what appeared to be dendritic reactive for CD163, but they were not seen in all
cases.
Figure 9. Immunohistochemical reactivity of CD163 in GCTs and Schwannomas.
Immunoreactivity was detected by DAB (brown colour). Images were taken using 200x original
magnification. a) GCT staining was negative. B) Schwannoma stained with high intensity and
punctate appearance in the majority of cells

a)

b)
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4.2.8 Qualitative evaluation of CD40 staining
Schwannomas and GCTs were both found to have no to scant staining of CD40 immunoreactivity
(Figure 10). Some sections for both tumours had some cells with a dendritic appearance staining
positive for CD40.
Figure 10. Immunohistochemical reactivity of CD40 in GCTs and Schwannomas.
Immunoreactivity was detected by DAB (brown colour). Images were taken using 200x original
magnification. a) GCT staining was negative. B) Schwannoma staining was negative

a)

b)
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4.2.9 Qualitative evaluation of CD11c staining
Schwannomas and GCTs were both found to have no to scant staining of CD11c immunoreactivity
(Figure 11). Some sections for both tumours had some cells with a dendritic appearance staining
positive for CD11c.
Figure 11. Immunohistochemical reactivity of CD11c in GCTs and Schwannomas.
Immunoreactivity was detected by DAB (brown colour). Images were taken using 200x original
magnification. a) GCT staining was negative. B) Schwannoma staining was negative

a)

b)

4.3 Semiquantitative Analysis using manual scoring.
Tables 6.1 and 6.2 show cumulative scores for percentage of cells stains and stain intensity for
GCTs and Schwannomas. This data was used to complete statistical comparisons between GCTs
and Schwannomas for our semiquantitative scoring system.
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Table 6.1 Percentage of cells staining positivity for IHC reactivity in GCTs and Schwannomas.
Case 2 of GCT did not have a section for CD163 IHC
IHC antibody
Tumour type
0 (0%)
1 (>0<50%)
2 (>50%)
GCT
23
S100
Schwannoma
10
GCT
23
NSE
Schwannoma
10
GCT
1
22
SOX10
Schwannoma
10
GCT
23
GAP43
Schwannoma
3
7
GCT
23
HLA-DR
Schwannoma
10
GCT
23
CD68
Schwannoma
1
6
3
GCT
22*
CD163
Schwannoma
10
GCT
23
CD40
Schwannoma
10
GCT
23
CD11c
Schwannoma
10
Table 6.2. Objective assessment of mean DAB stain intensity in GCTs and Schwannomas
Case 2 of GCT did not have a section for CD163 IHC
IHC antibody
Absent
Low
Medium
High
GCT
23
S100
Schwannoma
10
GCT
3
20
NSE
Schwannoma
4
6
GCT
1
22
SOX10
Schwannoma
10
GCT
2
21
GAP43
Schwannoma
4
6
GCT
6
17
HLA-DR
Schwannoma
4
6
GCT
17
6
CD68
Schwannoma
1
6
3
GCT
22*
CD163
Schwannoma
1
9
GCT
23
CD40
Schwannoma
10
GCT
23
CD11c
Schwannoma
10
-
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4.3.1 Investigating the difference between intensity and percentage
variables
A contingency table was constructed with the ordinal variable percentage cells staining as the xvariable and staining intensity as the y-variable.

A linear-by-linear association test was

completed. The p-value <0.0000000000000002, identifies that the two variables are almost
perfectly correlated. We rejected the null hypothesis that there is no association between the
variables: percent cells stained and cell stain intensity. Assuming the correlation between
variables, we chose to complete further analysis using only the ordinal variable for staining
intensity and can extrapolate our findings to percent cells staining.

4.3.2 Investigating the Difference between GCT and Schwannoma for
all antibodies using data obtained from semiquantitatve method

For each antibody used, a chi-squared table was constructed using the ordinal variable (staining
intensity) as the x-axis and nominal variable (cell type) as the y-axis. Given that we are performing
multiple tests, a Bonferroni correction was applied. CD40, CD11c, and S100 antibody scoring was
identical between GCTs and Schwannomas. Without variance between these three data sets, we
were unable to complete a statistical analysis, but can assume that there is no statistical
difference in the staining patters between GCTs and Schwannomas for the antibodies S100, CD40
and CD11c. Our Bonferoni correction was m = 6 (6 tests), and our new alpha value is αbonferroni =
0.05/6 = 0.0083.
We found no statistical difference between the staining intensity for the antibodies SOX10 (p=
0.5), GAP43 (p= 0.03), HLA-DR (p = 0.4). As previously mentioned, statistical analysis was not
completed for the antibodies S100, CD40 and CD11c, but without variance between their staining
intensities there is no significant difference in the staining intensity for these antibodies (p= 1).
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Significant higher stain intensity was identified for GCTs the antibodies NSE (p= 0.000008), CD68
(p = 0.0001) . CD163 had significantly higher stain intensity for Schwannomas (p= 0.00000007).
An additional Cochrane-Armitage test was completed to compare the cell staining intensity
across all variable for GCTs and Schwannomas. The staining intensities were compiled into a
single chi-squared table. A significant difference was identified between the overall staining
intensities for GCTs and Schwannomas (α= 0.05, p=0.000004).

4.4 H-score analysis obtained from QuPath Bioimage analysis
As previously described, QuPath was used to digitally identify cells staining positive, which were
then further stratified into low, medium and high staining intensities. In Table 7. data for percent
cells staining positive and the h-score are provided.

Table 7. Summary of % cells staining positive and H-score obtained from QuPath Bioimage
analysis.

Tissue type

GAP43

%

HLA-DR

H-score

positive

GCT

Schwannoma

%

CD68

H-score

positive

%

CD163

H-score

positive

%

H-score

positive

81.79 +/-

121.39

78.63 +/-

142.90

88.52 +/-

188.11

10.14 +/-

10.54 +/-

10.95

+/- 52.18

12.4

+/- 77.26

11.42

+/-41.94

7.67

8.03

32.86 +/-

38.53 +/-

83.00 +/-

168.16

24.07 +/-

27.7 +/-

68.43 +/-

90.11 +/-

15.12

20.50

16.67

+/- 89.49

10.2

13.13

15.22

35.34
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4.4.1 Investigating the Difference between GCT and Schwannoma for
GAP43, HLA-DR, CD68 and CD163 using H-score
During our statistical analysis, it became apparent that the distribution of H-score may follow a
non-Gaussian distribution, however given the low case count it was difficult to perform an
analysis of variance. We elected to proceed with both student’s t-test for Gaussian distribution,
and Welch’s t-test for non-Gaussian distribution. Again, a Bonferroni correction was applied with
m = 4 (4 tests) resulting in αbonferroni = 0.05/4 = 0.0125. Comparisons of H-score between GCT, and
Schwannoma for GAP43, HLA-DR, CD68 and CD163 antibodies are demonstrated in Figures 12.112.4.

Figure 12.1 H-score for GCTs and Schwannomas for anti-GAP43 antibody, a) Statistical
comparison using student’s t-test ( 𝛼= 0.0125, p= 0.0108), b) Statistical analysis using Welch’s ttest correction (𝛼= 0.0125, p= 0.0201) # p ≤ 0.0125

a)

b)
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Figure 12.2. H-score for GCTs and Schwannomas for anti-HLA-DR antibody, a) Statistical
comparison using student’s t-test (𝛼= 0.0125, p= 0.646), b) Statistical analysis using Welch’s ttest correction (𝛼= 0.0125, p= 0.646)

a)

b)

Figure 12.3. H-score for GCTs and Schwannomas for anti-CD163 antibody, a) Statistical
comparison using student’s t-test (𝛼= 0.0125, p= 0.0012), b) Statistical analysis using Welch’s ttest correction (𝛼= 0.0125, p= 0.0062) # p ≤ 0.0125, ## p≤ 0.005

a)

b)
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Figure 12.4. H-score for GCTs and Schwannomas for anti-CD68 antibody, a) Statistical
comparison using student’s t-test (𝛼= 0.0125, p< 0.0001), b) Statistical analysis using Welch’s ttest correction (𝛼= 0.0125, p= 0.0006), ### p≤ 0.001

a)

b)
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4.5 Comparing the manual scoring percentage of cell stained positive
to digital bioimage analysis using QuPath
We compared the percentage cells staining for both manual and digital scoring using QuPath in
Table 8. Statistical analysis was not performed for cell staining percentage. There appears to be
a correlation between the Manual scoring percent cells staining positive and the positive staining
cells in QuPath as the value of our semiquantitative manual score falls within the standard
deviation obtained from positive cell detection using QuPath.

Table 8. Average percentage of cells staining positive for GCTS and Schwannomas.
Summary of semiquantitative score using the average ordinal value for manual scoring of percent
cells staining (0=0%, 1= >0<50%, 2= >50%) and positive cell detection using QuPath
IHC Antibody
Tumour type
Manual scoring
QuPath
GAP43
GCT
2
81.79% +/- 10.94
Schwannoma
1.7
32.86 +/- 15.12
HLA-DR
GCT
2
78.65 +/- 12.38
Schwannoma
2
83.04 +/- 16.66
CD68
GCT
2
88.52 +/- 11.42
Schwannoma
1.2
24.07 +/- 10.2
CD163
GCT
0
10.14 +/- 7.67
Schwannoma
2
68.43 +/- 15.22

4.6 Comparing the manual intensity of cell staining to H-score
We compared the digital scoring (H-score) to manual scoring intensity of cell staining using
Pearson’s correlation coefficient and Pearson’s correlation for continuous variables (T-test).
Results are summarized in Table 9. All comparisons suggested statistically significant evidence
that there was a near perfect correlation between the manual scoring of cell staining intensity
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and the H-score derived from digital analysis using QuPath. A Bonferroni correction was not
applied as the p-values for all analysis were extremely low.

Table 9. Summary of the comparison of cell stain intensity using manual semiquantitative
scoring and H-score derived from QuPath

Antibody
All tumours

Correlation (r) 95% CI
0.906
0.827-0.949

P-value
0.000000000000001

GCTs only

0.903

0.767-0.961

0.00000005

Schwannomas only

0.9

0.759- 0.960

0.00000007

GAP43

0.92

0.689-0.981

0.0002

HLA-DR

0.961

0.841-0.991

0.000009

CD68

0.989

0.951-0.997

0.00000007

CD163

0.979

0.911-0.979

0.0000008

4.7 Results for RT-qPCR of GCTs
In this section, I will review the RNA data from the 11 FFPE sections, and RT-qPCR results for
CD68, Nestin, SOX2, SOX9, SOX10, NF2, GFAP, β-Tub3. Transcripts were detected by SYBR
fluorescence and reported as Cq values (threshold cycle). Statistical analysis was not performed.
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4.7.1 RNA concentration obtained from FFPE blocks
Using the Qubit Quan-iT RNA BR assay kit and Qubit fluorometer, RNA concentration of the 11
selected cases of GCT were determined (Table 10). Sufficient RNA concentration to proceed with
RT-qPCR was identified in 6/11 cases.

Table 10. Concentration of RNA extracted from FFPE tissue punches.*= RNA concentration
insufficient to proceed with RT-qPCR
Case #
1
3
6
7
8
15
16
17
18
22
23

RNA concentration (µg/mL)
6.5
17.4
4.24*
2.88*
5.7
7.4
Low*
2.2*
10
4.16*
6.5

4.7.2 Summary of Cq value obtained using RT-qPCR
RT-qPCR was used to detect the presence of cDNA, and reported as the Cq value, the replication
cycle where signal was detected above baseline. No Statistical analysis was performed using the
RT-qPCR data, results are observational/qualitative only.
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β-actin was used as a housekeeping gene in this investigation to verify the integrity of mRNA
obtained from FFPE tissues. β-actin mRNA was detected in 6/6 cases, and not in the NTC
indicating that there was likely to be cDNA in sufficient quantity and quality for interpretation of
the Cq results for the other 8 genes. It should be noted that case 18 and 23 showed high number
of copies of cDNA synthesized. Raw Cq values for β-actin are summarized in table 11.1.

Table 11.1 Summary of B-actin transcripts reported as Cq value. -- fluorescence not detected
Case#
1
3
8
15
18
23
NTC

Cq
34.70
37.38
36.94
34.53
29.71
28.89
---

CD68 was identified in 5/6 specimens by RT-qPCR. Case #1 had no CD68 transcripts, despite
staining densely positive in all granular cells using IHC. Cases 3, 8, 15, 18, and 23 were positive
for CD68 mRNA. Raw Cq values for CD68 is summarized in table 11.2.

Table 11.2. Summary of CD68 transcripts reported as Cq value. -- fluorescence not detected
Case#
1
3
8
15
18
23
NTC

Cq
-37.15
35.96
37.12
32.53
25.60
---
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With exception of case # 23, including the NTC, none of the other cases showed detectable levels
of SOX2, SOX9, SOX10, NF2 or Nestin. Transcripts were detected in cases #18 and 23 for β-Tub3,
while all others were negative. No cases showed SOX2 or GFAP transcripts. Cq values for Case
#23 are summarized in Table 11.3.

Table 11.3 Summary of Cq values for Case #23. -- fluorescence not detected
CD68
Nestin
SOX2
SOX9
SOX10
NF2
GFAP
Beta Actin
Beta TUB3

29.60
39.02
-36.18
38.01
37.14
-28.89
36.72
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Chapter 5
5.0 Discussion
5.1 Clinical Features
The mean age of patients diagnosed with a GCT was 41.4 ± 13.1 years, with the highest
prevalence in the 4th-6th decade, and the ratio of females to males was 1.6:1. The mean age of
cases is within the standard deviation of the reported mean age from larger case series which
ranges from 31-37 yrs old4,5, and is consistent with the WHO epidemiological data on GCTs8. In
our investigation, the sex ratio of females to males, was lower than the published ratio of the
WHO of 2:18, however there was still a female predilection. We did not record race as this data
was not readily available. For Schwannomas, we had a male: female ratio of 8:2 with a mean age
of 25 ± 9 years. The mean age is consistent with the age of diagnosis for Schwannomas, however
the expected sex predilection is 1:1. This would suggest that our sample has the potential for
bias should sex play a role in gene expression.
All GCTs and Schwannomas were tissue taken from the oral cavity. The most common location
for GCTs was the dorsal tongue at 69.5%, which is the most common location for GCTs in the oral
cavity. There was no tissue predilection for Schwannomas. It is possible that GCTs of the oral
cavity could express different proteins than their non craniofacial counterparts. This could make
generalization of our report to non-oral cavity GCTs challenging. We recognize the lack of tissue
availability, and as a result the absence of analysis of tissues from non-oral cavity sites, as a
potential confound. There is no consensus if trauma plays a role in the formation of either GCTs
or Schwannomas, however the anatomical location of tumours in regions that are frequently
traumatized by the dentition suggests that trauma may play a role in the formation of both of
these tumours.
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5.2 Comparison between IHC cell stain intensity and H-score derived
from QuPath
Recently, there has been an increased interest in using digital imaging analysis in both research
and clinical applications as a method of both quantitatively detecting cells positive for
immunoreactivity and objectively measuring staining intensity of positive cells. Stain intensity
can give insight into relative protein content indicating increased activity of a target protein and
its cellular function182,183.

Traditionally, our lab has used semiquantitative analysis of

immunoreactivity using traditional light microscopy. It was our intention during this project to
initiate a method of digitally analyzing slides that could be used for future investigations. Our lab
selected QuPath, a free open source digital bioimage analysis software that has been validated
for its accuracy and reproducibility of results184,185. A benefit of using digital analysis is that one
can create a workflow script that can be applied to all images in a project so that all images are
analyzed with the same parameters. In our study, we completed Pearson Correlation Coefficient
analysis, comparing H-score to cell stain intensity, for GAP43, HLA-DR, CD163 and CD68, and
composites for each tumour and all sections. For all analysis, there was a near perfect correlation
suggesting that there was no difference in the results obtained using each scoring methods. This
can be interpreted as validating both methods of section analysis as a high H-score is predictive
of a high semiquantitative score and vice versa. We recognize that our limited ability to have
sections scanned using the Aperio scanner resulted in a low case count (5 sections of GCT and 5
sections of Schwannoma for each IHC antibody). However, given the high degree of correlation
between H-score and our manual semiquantitative analysis of cell staining intensity our opinion
is that the case count is adequate and representative of data we would obtain if we had digitized
all sections included in the manual analysis.

5.3 Review of antibodies supporting a NCC origin of GCTs
While some of the antibodies employed in our investigation, NSE and S100, have had their
specificity called into question, collectively this report provides a strong body of evidence to
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support a NCC cell of origin for GCTs and the similarity of GCT and Schwannoma immunoreactivity
would suggest that they likely develop from the same cell type. As expected, both GCTs and
Schwannomas were found to stain with high intensity in all cells for S100 antibody.
Polyclonal S100 is one of the most commonly used antibodies employed by Pathologists to assist
with differentiating spindle cell lesions originating from NCC and non-NCC origins. The S100
polyclonal antibody used in this investigation has highest specificity for S100B, but also low
specificity to S100A1 and S100A6. S100A1 is abundant in skeletal muscle119, while S100A6 is not
cell specific but elevated levels have been associated with tumourigenesis of common
malignancies and thought to be increased as a stress response186. There is copious evidence to
suggest that neural and glial cells expresses a high level of S100 protein, particularly S100B in
their healthy state120. It is also generally accepted that all benign and most malignant tumours
originating from NCCs stain positive for polyclonal S100 immunoreactivity120. In contrast to the
presumed specificity of S100B, a variety of tumours and cells originating from all germ layers can
be induced to express S100 proteins particularly S100A8, S100A9, S100A12 and S100B as a result
of oxidative stress and tissue inflammation119. The strong intensity of SOX10 immunoreactivity
provides additional evidence of a NCC origin for GCTs, and is emerging as a more specific marker
of NCC origin than S100. It is interesting to note that Case #21 was non-reactive for SOX10
immunoreactivity while staining with strong intensity in most cells for S100.

Negative

immunoreactivity to SOX10 was confirmed by repeating SOX10 IHC on a second section of case
#21. SOX10 has been shown to stain positive for virtually all BPNST, however there are several
reports identifying absence of SOX10 staining in MPNST in 30% of tumours, which can be
problematic for pathologists in diagnosing malignant spindle cell lesions187. We were unable to
find a case report identifying either peripheral benign or malignant GCTs that stained negative
for SOX10 but positive for S100. Of note, central GCTs which are presumed to develop from an
astrocyte origin and have virtually identical histological appearance to peripheral GCTs were
found to stain negative for SOX10188. The SOX10 sections for case #21 were reviewed with two
experienced pathologists. As a consequence of freeze artifact, the tumour architecture was
distorted but the histological diagnosis of GCT was confirmed. The section also did not appear
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to show evidence of malignant transformation. We considered excluding case #21 from our
investigation but ultimately decided that the tissue was still interpretable for histopathology.
Explanation for the lack of SOX10, in the context of the remainder of the staining profile of case
#21, could either be that during tumourigenesis the tumour lost SOX10 expression, or that the
lack of SOX10 staining was a consequence of freezing during tissue transport. In contrast, there
are several case reports identifying GCTs to be negative for S100, but positive for SOX10 both
from the oral cavity and other anatomical sites. It is unclear if these tumours referred to as
primitive GCTs are derived from mesenchyme of a NCC origin that differs from traditional GCTs,
or if these tumours have lost S100B expression189. While both GCTs and Schwannomas stained
positive for NSE providing support of a NCC origin, an interesting finding of this investigation was
that GCTs stained with higher intensity in a greater percentage of cells than Schwannomas for
NSE. A higher intensity of NSE staining in GCTs may indicate that GCTs have a higher metabolic
demand than Schwannomas as there are multiple reports that NSE is upregulated in both
tumours derived from NCC and non-NCC derived turmors during inflammation and hypoxic
stress.
This report is the first to identify GAP43 immunoreactivity of GCTs, with strong stain intensity in
most granular cells. As of yet, their role in glial cells has yet to be determined, however there is
evidence to suggest that they play a role in promoting outgrowth of neurites during development
and also following nerve injury in growth cone formation139. It is interesting to note that GAP43
is expressed in RSC and SCP but not mature SC. Its expression also occurs late following nerve
injury at 4 weeks which suggests that its expression occurs late in Wallerian degeneration
following clearance of myelin debris190. In comparison to S100 and SOX10, GAP43 is a relatively
newly discovered protein. It appears to be highly specific as a marker of neural and glial tissues.
In contrast to S100 and SOX10, GAP43 expression is also retained in MPNST and has recently
been suggested to have a higher sensitivity and specificity for NCC derived spindle cell
malignancies than either S100 or SOX10141.

Recent studies have identified GAP43

immunoreactivity in a variety of malignancies including papillary thyroid cancer143, non-small cell
lung cancer144 and some breast cancers145 calling into to question the presumed specificity of
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GAP43 and suggesting that it has additional, yet to be determined roles in tumorigenesis.
Additionally, tumours expressing GAP45 have a higher risk of intracranial metastasis145. GAP43
immunoreactivity provides new evidence that GCTs originate from NCC and provides the
strongest evidence yet that GCTs likely develop from Schwann cells. It is also the first antibody
to suggest that the granular cells of GCTs have a cell phenotype similar to RSC or SCP than mature
SCs.
Another finding in this report that has not been described was the architecture of Schwannoma
GAP43 staining. Immunoreactivity of the cell rich Antoni A region was found to stain with high
intensity in most spindle cells, while the Antoni B region was found to stain with low intensity in
less than 50% of the spindle cells. Antoni B regions are generally thought to be degenerated
regions of Schwannomas associated with inflammation such as hyalinization, fibrosis, mucin
inclusion, thrombosis, and macrophage and lymphocyte infiltration93,98. Greater staining of the
Antoni A regions would suggest that GAP43 immunoreactivity and protein expression decreases
as the spindle cells of Schwannomas begin to lose the architecture of Antoni A areas and
transition to Antoni B areas. This would also suggest that the granular cells of GCTs are more
similar to the spindle cells found in the Antoni A areas than the Antoni B areas.

5.4 Review of antibodies supporting an APC phenotype
Collectively, evidence from this investigation provides evidence of an APC phenotype or some
APC-like features for GCTs. At the onset of our investigation, the function of the increased
lysosome content of the granular cells were unknown, and it was unclear if GCTs were reactive
lesions or tumours. Consistent with other reports, this investigation identified strong staining
intensity in the majority of granular cells for CD68 antibody indicating that the granules are
lysosomes. CD68 is generally accepted as a cell marker for tissues with phagocytic function such
histiocytes, monocytes, giant cells, Kupffer cells, and osteoclasts, and it expression is thought to
be regulated by a macrophage specific promoter gene155,156. It had been theorized that
lysosomes of GCTs may indicate a phagocytic function of GCTs following nerve injury. The
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presence of an abnormal number of lysosomes has now been explained by the work of Pareja et
al, who have identified a novel mutation of the ATP6AP1 and ATP6AP2 genes coding V-ATPase
accessory proteins which have roles in endosome acidification and transport36. The findings of
Pareja et al. provide clear genetic evidence to explain the intensity of CD68 immunoreactivity,
and confirm the theory that the accumulation of lysosomes is a result of altered lysosomal
transport and function. Additional support of an APC phenotype for GCTs is from the strong
intensity of immunoreactivity for HLA-DR. HLA-DR expression is associated with by APCs
including B lymphocytes, activated T lymphocytes and professional APCs (monocytes,
macrophage and dendritic cells).

We had theorized that in combination with CD68

immunoreactivity, HLA-DR immunoreactivity would suggest that GCTs may be reactive in nature
and have a role in antigen presentation during the innate immune response. This theory is
disproven by evidence that the lysosomes of GCTs are non-functional and negative reactivity for
the costimulatory molecule CD40 suggest that GCTs cannot participate in T-cell activation. Given
that GCTs are thought to have malignant potential, it is plausible that HLA-DR expression serves
a role in GCTs analogous to HLA-DR expression by melanomas. In melanomas, HLA-DR is thought
to be associated with tumour-antigen presentation, tissue inflammation, and an immune
response against tumour cells, and is a positive prognostic factor for survival191. A third
explanation is that the presence of HLA-DR immunoreactivity may suggest an epithelialmesenchymal transformation with HLA-DR immunoreactivity more indictive of tissue
dedifferentiation and an APC phenotype rather than serving a role in antigen presentation.
Finally, a fourth possible explanation is that expression of HLA-DR indicates tissue inflammation
as HLA-DR expression has been reported in several cell populations including sinusoidal
endothelial cells and hepatocytes, 150, respiratory epithelium and gastrointestinal epithelium151
and conjunctiva152 during tissue inflammatory responses. HLA-DR immunoreactivity has not been
previously described in Schwannomas. At the onset of our investigation we presumed that HLADR would stain negative for immunoreactivity in the spindle cells of Schwannomas, however all
sections of Schwannomas stained positive for HLA-DR with moderate to high intensity. This
surprising finding could be explained by the same theories proposed for GCT HLA-DR expression.
While immunoreactivity of Schwannomas to HLA-DR has not been reported, expression of HLA-
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DR has been reported in gliomas and neuroblastomas192. In gliomas and neuroblastomas, HLADR expression is thought to be associated with increased tumour inflammation and patient
outcomes are worse in tumours expressing higher levels of HLA-DR192.
The negative immunoreactivity of GCTs for CD163, CD40 and CD11c do not provide support of an
APC phenotype of GCTs. An interesting finding that has not been previously reported was the
strong intensity of Schwannoma immunoreactivity for CD163. The upregulation of CD163 in
Schwannomas could possibly be explained by a cell phenotype of the spindle cells of
Schwannomas similar to the phagocytic phenotype of RSCs, and also serve as a marker of an
inflammatory process. On sections of GCT we identified cells with a dendritic appearance that
had reactivity to CD163. This supports inflammation within GCTs which could result in HLA-DR
expression but does not provide support of an APC phenotype for GCTs.

5.5 Interpretation of raw RT-qPCR data
β-actin was used as a housekeeping gene to verify the integrity of mRNA obtained from FFPE
tissues. Housekeeping transcripts were detected in 6/6 cases, and not in the NTC. Given the
strong body of evidence of CD68 IHC immunoreactivity, we chose to investigate CD68 mRNA
expression as a positive control, expecting that we would find high levels of CD68 mRNA present
in all cases. CD68 mRNA was identified in 5/6 specimens. Case #1 did not show detectable CD68
mRNA, despite staining densely positive in all granular cells using IHC.
Case #23 demonstrated positivity for Nestin, SOX9, SOX10, NF2, and β-TUB3 transcripts. β-TUB3
gene expression indicates that there was likely neural tissue present in the cores obtained from
the FFPE blocks making interpretation of RT-qPCR results of this case challenging.
Surprisingly SOX10 mRNA was only found in case 23 and not in 5/6 other cases. Lack of SOX10
cDNA is in stark contrast to previously published literature regarding GCT immunoreactivity to
SOX10 and is inconsistent with the IHC findings of this investigation. Given that RT-qPCR is more
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sensitive and specific that IHC, this result is perplexing. One possible theory is that SOX10 may
be a stable protein, such that protein levels are detected despite low levels of mRNA. One other
possible explanation is that SOX10 mRNA is more susceptible to degradation. Degradation could
have occurred from chemical binding and degradation during formalin fixation and paraffin
infiltration, or from poor tissue storage, as the FFPE blocks were stored at room temperature in
an uncontrolled environment for as long as 12 years. Fragmented mRNA would still be detected
using Qubit fluorescence. Without positive SOX10 transcript levels, it is challenging to draw
conclusions from Nestin, SOX2, SOX9, SOX10, NF2 and GFAP mRNA data.

5.6 Other lesions with a granular appearance
Reviewing the literature identified greater than 40 soft tissue lesions of the head and neck region
that are characterized by a granular appearance. These lesions include both malignant and
benign entities derived from odontogenic, fibroblastic, histiocytic, myoblastic and neural cells of
origin193. In this section, I will give a brief review of several of these entities and their presumed
histogenesis. Similar to GCTs the cellular processes that lead to accumulation of lysosomes or
other granular inclusions are mostly unknown.
A relatively rare lesion with near identical histological appearance to GCTs is the congenital epulis
of newborn (CEN) or congenital granular epulis. Unlike GCTs, the most common location is the
alveolar ridge with a predilection for the maxilla. While generally less than 1 cm in size, lesions
can be larger resulting in feeding difficulties or possible airway obstruction193. On histology, CEN
are characterized by large polygonal cells with eosinophilic granular cytoplasm arranged in
clusters with scant connective tissue and atrophic mucosa without pseudoepitheliomatous
hyperplasia. CEN can be differentiated from GCTs by their IHC profile. Evidence to suggest a
differing cell of origin than GCTs are supported by the non-reactive IHC for s100, CD68, and p75
antibodies. In CEN the granules thought to represent lysosomes, have been found to stain
positive for collagen suggesting they are of a myofibroblastic cell line of origin194. It is unclear if
CEN are reactive lesions or tumours.
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There are a group of tumours derived from odontogenic epithelium including, granular cell
ameloblastoma (GCA), Central Granular cell odontogenic tumour (CGOT), granular cell
ameloblastic fibroma (GCAF), calcifying epithelial odontogenic tumour, and granular cell
odontogenic cyst193. Unlike GCTs, GCA tend to appear heterogenous with granular cell islands
interspersed with an epithelial stroma. In GCA, granular change is indicative of an aggressive
variant of ameloblastoma, and is concerning for malignant change, and metastasis. The granular
cells demonstrate great variability in granule size and are thought to represent ancient change
as they tend to be found centrally while the peripheral tumour architecture maintains a stellate
reticulum pattern193. It is generally accepted that the granules ae lysosomes, although it is
unclear if the granular cells are a result of ongoing phagocytosis or a change in cell morphology
similar to GCTs. They are reactive for CD68, and cytokeratin, but non-reactive for s100, vimentin,
and NSE refuting a NCC origin and supporting an epithelial origin195. The CGCOT has granular
cells arranged in sheets and lobules interspersed with cords of odontogenic epithelium, without
stellate reticulum. The granular cells are thought to originate from fibroblasts as on histology
there appears to be a transformation from fibroblast at the periphery to granular cells centrally
with an increased granular appearance thought to be lysosomes. Due to the rarity of the lesion
the IHC profile has been poorly explored, but case series have identified that they stain for
vimentin and CD68, but negative for S100 and NSE immunoreactivity. Collectively the histological
and immunohistochemical findings are interpreted to suggest a mesenchymal transformation of
fibroblasts similar to CEN196. Another group of lesions restricted to the head and neck region
include benign and malignant salivary gland tumours.
Other soft tissue lesions that can arise in any region of the body that can have a granular cell
change include, leiomyoma, rhabdomyoma, neurilemmona, dermatofibroma, and their
associated sarcomas. Hodgkins’ lymphoma also has cells with a granular appearance, as do some
tumours of histiocytic origin such as langerhan histiocytosis and verruciform xanthoma193. There
are also lesions that can metastasize to the head and neck including the granular cell variant of
renal cell carcinoma, hepatocellular carcinoma, and breast adenocarcinomas that are
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characterized by cells with a granular appearance. Granular cells can also be seen in melanomas
and basal cell carcinomas193. It is important for the Pathologist to be aware of these other lesions
when considering a histopathological diagnosis of GCT to ensure that patients receive the most
appropriate course of treatment.

5.7 Limitations of this study
While digital analysis is likely more accurate than objective scoring methods, and certainly seems
to be better at detecting small differences in staining intensity, there are several criticisms of
whole slide analysis using QuPath. Firstly, cell detection relies on QuPath detecting cell nuclei
and then using programed algorithms to determine the boundaries used for cell borders. While
analysis of nucleus staining is highly accurate, the algorithmically calculated cytoplasmic
expansion may not be truly representative of actual cell membranes and the contents of cell
cytoplasm. This results in inaccuracies when analyzing IHC stains either restricted to the
cytoplasm or those that stain both cytoplasm and the nucleus. Another concern identified during
cell detection was that the nucleus diameter is set manually. If the diameter was set too high
then nuclei of positive staining cells were missed in the analysis. In contrast when the nuclear
diameter was set to capture the majority of positive cells there was incidence of nucleus
fractioning based on variations of the optical density of the hematoxylin stain within the nucleus
that were interpreted as separate nuclei by the QuPath algorithm. This resulted in an artificially
increased number of cells detected in both positive and negative cells. During analysis we made
the assumption that nucleus fractioning was the same for both positive cells and negative cells
which would not affect the H-score as the formula for H-score is based on the percentage of cells
staining positive at low medium and high intensity. A third concern identified during QuPath
analysis was that when performing whole tumour analysis all cells with nuclei smaller than the
programed diameter are identified during cell detection including those that are not of interest.
It is possible to manually exclude individual cells from your assessment however for most of the
tumours the cell count was greater than 50 000 cells, with some tumours having cell counts as
high as 120 000. This error during digital analysis was most apparent during QuPath analysis of
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GCT sections for CD163. During manual scoring it was evident that there were a number of cells
that stained positive in sections of GCTs that had a dendritic appearance suggesting presence of
inflammation within the tumour, while all granular cells appeared to stain negative for CD163
immunoreactivity. As an example, using QuPath case 11 had positive cell identification of 21%
for CD163 while case 9 had only 1.6% positive cell identification. An alternative approach to
whole slide imaging is to select regions of the tumour for analysis with a more manageable cell
count, however this can result in selection bias if the chosen region is not representative of the
entire tumour.

Finally, as the thresholds for low, medium and high staining intensity

corresponding to DAB optical density are entered manually interpretation of an H-score should
only be made between tissues that were assessed using the same algorithm. Light microscopy
of sections can suffer from analysis errors such as selecting fields that are not representative of
the tumour, varying conditions such as microscope brightness, and errors in interpreting cell
immunoreactivity could result in diagnostic or scoring errors. Recognize that DAB staining
intensity can be relative to the duration that the tissue section is exposed to DAB during tissue
processing, the use of subjective cell stain intensity as a measure of protein content is not a
precise measure, and interpretation of cell function should be used cautiously. Additionally, while
identifying cells that stain positive for an antigen is suggestive of upregulation of the protein, it
is possible that there is cross reactivity between other proteins with a similar structure. Cross
reactivity of SOX10 in GCTs must be questioned due to the absence of SOX10 mRNA. In light of
a strong body of evidence that GCTs are immunoreactive for SOX10, we believe the absence of
SOX10 mRNA may be due to technical issues.

5.8 Future work
Recognizing that mRNA extraction from FFPE is challenging and highly technique sensitive, it
could be valuable to repeat our RT-qPCR experiments investigating a NCC developmental
phenotype of GCTs using an alternative RNA isolation protocol. It would also be of value if either
fresh tissue or fresh frozen tissue were available to allow for more predictable RNA extraction
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and stability. Given the rarity of GCTs, and their benign presentation obtaining tissue before
formalin fixation is unlikely.
It is important for pathologists to be aware of the rare and atypical variants of tumours that can
have a granular cell appearance in order to make an accurate histopathological diagnosis given
the similarity of the histology for many of these lesions.

Correct identification requires

appropriate use of IHC antibodies, and correlation with the clinical presentation, anatomic
location and tissue architecture. Given that granular variants of many of these lesions are rare
little is known about their tumourigenesis. Generally, the accumulation of lysosomes is thought
to represent a mesenchymal change and dedifferentiation of the precursor cells with unknown
significance. More work needs to be done to explore the variety of lesions that can occur with
granular appearance. Specifically, it would be interesting to assess for mutations of lysosome
formation, acidification and transportation using gene sequencing similar to the methods used
to identify genetic mutations of ATP6AP1 and ATP6AP2 in GCTs. Given that the epidemiological
data indicates a higher female predilection it would be interesting to investigate ATP6AP1 and
ATP6AP2 gene expression of the inactivated X-allele. If ATP6AP1 and ATP6AP2 are co expressed
by the X and Xi chromosomes it could be a possible explanation for the higher female predilection
of GCTs.
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Chapter 6
6 Conclusion
This study provides new evidence of a NCC cell of origin for GCTs, likely originating from SC
lineage as supported by IHC immunoreactivity of GAP43. Specifically, GAP43 has been shown to
be expressed by SCP and RSC, but not mature SC suggesting that the GCT phenotype is more
similar to dedifferentiated SC than mature myelinating or non-myelinating SCs. We also provide
additional evidence of an NCC of origin by IHC immunoreactivity to NCC markers S100, SOX10
and NSE. While we provided evidence of HLA-DR and CD68 immunoreactivity, other commonly
used IHC antibodies supporting an APC phenotype CD163, CD40 and CD11c were non-reactive.
Collectively the IHC evidence provides weak evidence of an APC phenotype for GCTs.
We have also provided new evidence of Schwannoma IHC immunoreactivity for CD163,
suggesting either a phagocytic phenotype analogous to repair SCs or inflammation within the
tumour. This report is also the first to describe the differences in the staining patters of Antoni A
and Antoni B areas of Schwannomas for GAP43 providing support that Antoni B areas develop
from degenerated Antoni A areas.
Unfortunately, we were not able to provide molecular evidence of a NCC origin or identify a
developmental NCC phenotype of GCTs given the challenges faced during RT-qPCR. While PCR
has higher specificity and sensitivity than IHC, the lack SOX10 transcripts raises questions about
the methods used in RNA extraction and cDNA synthesis and the quality and quantity of RNA
extracted. Reliable qPCR data would have allowed us to make conclusions about similarities of
GCTs to SC developmental stages. Access to fresh or frozen tissue would improve the validity of
RT-qPCR results and could provide definitive evidence of an NCC origin for GCTs.
As a result of the strong evidence that GCT tumourigenesis is from NCCs, most likely SCs, we
propose that GCTs should be added to the PNST classification system. Additionally, as a granular
cell appearance is not unique to GCTs we propose a name change to Granular Nerve Sheath
Tumour which is more descriptive of this rare lesion.
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Appendix:
Manual scoring of anti-S100 antibody for GCT
Case #

Intensity

Percentage
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Manual scoring of anti-SOX10 antibody for GCT
Case #

intensity

Percentage
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Manual scoring for anti-NSE antibody for GCT
Case #

intensity

Percentage
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Manual scoring for anti-GAP43 antibody for GCT
Case #

intensity

Percentage
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Manual scoring for anti-CD68 antibody for GCT
Case #

intensity

Percentage
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Manual scoring for anti-CD68 antibody for GCT
Case #

intensity

Percentage
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Manual scoring for anti-HLA-DR antibody for GCT
Case #

intensity

Percentage
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3

2
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Manual scoring for anti-cd163 antibody for GCT
Case #

intensity

Percentage

1

0

0

2

--

--

3

0

0

4

0

0

5

0

0

6

0

0

7

0

0

8

0

0

9

0

0

10

0

0

11

0

0

12

0

0

13

0

0

14

0

0

15

0

0

16

0

0

17

0

0

18

0

0

19

0

0

20

0

0

21

0

0

22

0

0

23

0

0
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Manual scoring for anti-cd40 antibody for GCT
Case #

intensity

Percentage

1

0

0

2

--

--

3

0

0

4

0

0

5

0

0

6

0

0

7

0

0

8

0

0

9

0

0

10

0

0

11

0

0

12

0

0

13

0

0

14

0

0

15

0

0

16

0

0

17

0

0

18

0

0

19

0

0

20

0

0

21

0

0

22

0

0

23

0

0
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Manual scoring for anti-cd11c antibody for GCT
Case #

intensity

Percentage

1

0

0

2

--

--

3

0

0

4

0

0

5

0

0

6

0

0

7

0

0

8

0

0

9

0

0

10

0

0

11

0

0

12

0

0

13

0

0

14

0

0

15

0

0

16

0

0

17

0

0

18

0

0

19

0

0

20

0

0

21

0

0

22

0

0

23

0

0
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Manual scoring for anti-S100 antibody for Schwannoma
Case #

intensity

Percentage

1

3

2

2

3

2

3

3

2

4

3

2

5

3

2

6

3

2

7

3

2

8

3

2

9

3

2

10

3

2

Manual scoring for anti-SOX10 antibody for Schwannoma
Case #

intensity

Percentage

1

3

2

2

3

2

3

3

2

4

3

2

5

3

2

6

3

2

7

3

2

8

3

2

9

3

2

10

3

2
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Manual scoring for anti-NSE antibody for Schwannoma
Case #

intensity

Percentage

1

2

2

2

2

2

3

1

1

4

2

2

5

1

1

6

2

2

7

2

2

8

1

1

9

2

2

10

1

2

Manual scoring for anti-GAP43 antibody for Schwannoma
Case #

intensity

Percentage

1

3

2

2

3

2

3

2

1

4

2

1

5

2

2

6

3

2

7

3

2

8

3

2

9

3

2

10

2

1
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Manual scoring for anti-CD68 antibody for Schwannoma
Case #

intensity

Percentage

1

1

1

2

2

1

3

1

1

4

1

1

5

2

2

6

1

2

7

0

0

8

1

1

9

1

1

10

2

2

Manual scoring for anti-HLA-DR antibody for Schwannoma
Case #

intensity

Percentage

1

3

2

2

3

2

3

2

2

4

3

2

5

3

2

6

2

2

7

2

2

8

2

2

9

3

2

10

3

2
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Manual scoring for anti-CD163 antibody for Schwannoma
Case #

intensity

Percentage

1

3

2

2

3

2

3

3

2

4

3

2

5

3

2

6

2

2

7

3

2

8

3

2

9

3

2

10

3

2

Manual scoring for anti-CD40 antibody for Schwannoma
Case #

intensity

Percentage

1

0

0

2

0

0

3

0

0

4

0

0

5

0

0

6

0

0

7

0

0

8

0

0

9

0

0

10

0

0
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Manual scoring for anti-CD11c antibody for Schwannoma
Case #

intensity

Percentage

1

0

0

2

0

0

3

0

0

4

0

0

5

0

0

6

0

0

7

0

0

8

0

0

9

0

0

10

0

0

H-score and percent staining positive for anti-GAP43 antibody in GCTs using QuPath digital
analysis
Case #

Positive %

H-score

1

95.15

180.98

9

91.97

176.03

10

76.08

85.31

11

71.26

82.84

14

74.47

81.81

H-score and percent staining positive for anti-CD68 antibody in GCTs using QuPath digital
analysis
Case #

Positive %

H-score

1

91.61

193.53

9

88.81

206.05

10

99.32

223.23
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11

93.58

202.14

14

69.29

115.59

H-score and percent staining positive for anti-HLA-DR antibody in GCTs using QuPath digital
analysis
Case #

Positive %

H-score

1

71.39

119.12

9

71.09

83.27

10

84.1

182.64

11

98.01

257.53

14

68.67

71.92

H-score and percent staining positive for anti-CD163 antibody in GCTs using QuPath digital
analysis
Case #

Positive %

H-score

1

6.195

6.217

9

1.814

1.87

10

14.57

15.58

11

21.14

21.84

14

6.981

7.204

H-score and percent staining positive for anti-GAP43 antibody in Schwannomas using QuPath
digital analysis
Case #

Positive %

H-score

1

32.65

39.7

3

21.87

23.82

4

16.33

16.77

5

38.51

42.68
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8

54.96

69.71

H-score and percent staining positive for anti-CD68 antibody in Schwannomas using QuPath
digital analysis
Case #

Positive %

H-score

1

22.7

25.92

3

32.21

35.75

4

21.66

23.06

5

34.8

44.38

8

8.978

9.756

H-score and percent staining positive for anti-HLA-DR antibody in Schwannomas using QuPath
digital analysis
Case #

Positive %

H-score

1

90.65

206.92

3

96.58

252.26

4

58.17

69.14

5

95.89

237.94

8

73.73

74.42

H-score and percent staining positive for anti-CD163 antibody in Schwannomas using QuPath
digital analysis
Case #

Positive %

H-score

1

77.5

107.57

3

57.54

72.13

4

64.44

75.29

5

89.96

142.66

8

52.73

52.89
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Curriculum Vitae

7

EDUCATION

2015 – present

Oral and maxillofacial Surgery resident, Schulich School of Medicine and
Dentistry, London Health Science Centre, London Ontario

2016 – 2020

MD, Schulich School of Medicine and Dentistry, Western University London
Ontario

2015 – present

Masters in pathology candidate, Western University Schulich School of
Medicine and Dentistry Faculty of Pathology

2013 – 2014

General Practice Residency, Foothills Medical Centre, Calgary, Alberta

2009 – 2013

DMD (honours), University of Manitoba Faculty of Dentistry, Winnipeg,
Manitoba

2010 – 2013

B.Sc. dent, University of Manitoba Faculty of Dentistry, Winnipeg, Manitoba

2006 – 2009

B.Sc. Biopsychology (Gold medal winner and honours), University of
Winnipeg, Winnipeg Manitoba

8

EMPLOYMENT

2014 – 2015

General dentist, Dental Choice, Calgary Alberta

2014

Locum tenancy, Foothills Medical Centre Dental clinic, providing clinic
supervision to general practice dental residents

2014

Surgical Assistant at Calgary Health Regional to Dr. Miller Smith, Dr. Graham
Cobb and Dr. Brett Hebijanic

2014

Surgical assistant at South Calgary Oral and maxillofacial, private OMFS clinic,
Calgary Alberta
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9

SCHOLARSHIPS AND AWARDS

2013

Graduate with Honours, achieved a minimum cumulative G.P.A. of 3.8

2012

Dean's Honours: achieved a minimum sessional G.P.A. of 3.8
Dr. Jack King Memorial Scholarship: top mark in Periodontology, Oral diagnosis
and Radiology
Dr. J.B. Rumberg and Dr. H Rumberg Memorial Prize: top mark in Oral diagnosis
and Radiology

2011

Endowment Fund Scholarship in Dentistry: high academic achievement while
demonstrating communication and leadership skills
Dr. John M. Grahame Scholarship: best combines scholastic achievement,
general character and participation in extra-curricular activities.
Winnipeg Police association scholarship: high academic standing

2010

Dean's Honours: achieved a minimum sessional G.P.A. of 3.8
Leonard Krueger Scholarship: high academic standing,
Wilhelm Kristjianson scholarship: A student of Icelandic descent with good
academic standing that displays qualities of leadership and community service
Winnipeg Police association scholarship: high academic standing

2006-2009

University of Winnipeg entrance scholarship 2006
University of Winnipeg academic merit scholarship 2007, 2008
Winnipeg police association scholarship 2006, 2007, 2008

PUBLICATIONS
1. Rogala B, Kerr Z, Shimizu M, (2018) Septic Arthritis of the Temporomandibular Joint in a 10 Year
Old: A Case Report and Literature Review, Journal of Oral and Maxillofacial Surgery, in press
April 2019
2. Rogala B, Li Y, Li S, Chen X, Kirouac GJ (2012) Effects of a Post-Shock Injection of the Kappa
Opioid Receptor Antagonist Norbinaltorphimine (norBNI) on Fear and Anxiety in Rats. PLoS ONE
7(11)
3. Aujla H, Hutton C, Rogala B,(2013) Assessing Anxiety and Reward- Related Behaviors Following
Alcohol Administration or Chronic Stress. J Alcoholism Drug Depend 1:136
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CITATIONS OF ACADEMIC PRESENTATIONS
1. Rogala B, Concomitant facial and cervical spine fractures in the geriatric population. 2018 Ontario
Society of Oral and Maxillofacial Surgeons residents night.
2. Rogala B, Jackson- Boeters, Khan Z, Lapointe H, Darling M. Phenotype of granular cell tumours.
2018 Western university Schulich school of medicine and dentistry department of Pathology
research day.
3. Rogala B, Jackson- Boeters, Khan Z, Lapointe H, Darling M. Investigating the etiology and
phenotype of granular cell tumours. 2017 Western university Schulich school of medicine and
dentistry department of Pathology research day.
4. Rogala B, Li Y, Chen XY, Li S, and Kirouac GJ. Effects of inactivation of kappa opioid receptors with
norBNI on sensitized fear following a single episode of footshock in rats. Neuroscience, 2011.
5. Rogala B, Li Y, Chen XY, Li S, and Kirouac GJ. Effects of inactivation of kappa opioid receptors with
norBNI on sensitized fear following a single episode of footshock in rats. 2012 Midwest Dental
Student Research Conference, 2012.
6. Ben Rogala, Yonghui Li, Xiaoyu Chen, Sa Li, Gilbert Kirouac. Effects of inactivation of kappa opioid
receptors on fear sensitization in a rat model of posttraumatic stress disorder. Manitoba Chapter
of Society for Neuroscience, 2011
7. Ben Rogala, Yonghui Li, Xiaoyu Chen, Sa Li, Gilbert Kirouac. Effects of inactivation of kappa opioid
receptors on fear sensitization in a rat model of posttraumatic stress disorder. University of
Manitoba Undergraduate Research poster competition, 2011
8.

Rogala B, Li Y, Chen XY, Li S, and Kirouac GJ. Effects of inactivation of kappa opioid receptors with
norBNI on sensitized fear following a single episode of footshock in rats. Manitoba Dentistry
Association , 2012.

RESEARCH GRANTS
1. CAOMS Research support grant, Canadian Association of Oral and Maxillofacial Surgeons
foundation for continuing education and research in support of a master’s thesis
2. Natural Science and Engineering Research Council of Canada (NSERC) undergraduate student
research grant. Prestigious undergraduate grant for promising young researchers
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ADDITONAL TRAINING
-

-

2018, AOCMF North America, Orbit fundamentals
o Didactic and practical application of trauma and reconstruction of orbit and midface
trauma
2017, AOCMF North America, management of facial trauma
o Didactic and practical introduction to approaches to facial trauma

-

2014 Certification from ADA&C continuing education for oral, nitrous and single agent
intraperitoneal sedation
Advanced Cardiac Life Support 2020
Pediatric Advanced Life support 2019
Advanced traumatic Life support 2013

-

Esthetic Alliance Program in dental implant esthetics 2014
Hands on Synthes Matrix and Sawbone workshops 2014 2018
Hands on training for restoring Nobel biocare implants 2014, 2016, 2017, 2018
Hands on training for restoring Denstply Astra implants 2014, 2018

PROFESSIONAL ORGANIZATIONS
-

Canadian Association of Oral and Maxillofacial Surgeons resident member
Ontario Dental Association
Royal College of Dental Surgeons of Ontario

ACADEMIC INVOLVEMENT
-

2012-2013 Communications director, Manitoba Dental Students Association
2010-2011 Class president and a member of the student faculty council
2010- 2013 Students Research Group at the University of Manitoba Faculty of Dentistry
2011- 2013 member of the ADEA coSRF

INTERESTS
-

Member of Balance Point Triathlon club in London Ontario
Member of East Side Riders cycling club
Member of Schulich School of Medicine and Dentistry hockey team
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